Acute Promyelocytic Leukemia, PML-RARA

MONDO:0012883 Pathograph 32 Show in embeddings browser acute myeloid leukemia

Acute promyelocytic leukemia (APL) with PML::RARA is a molecularly defined acute myeloid leukemia caused by a somatic PML::RARA rearrangement, most often the classic t(15;17) but sometimes a cytogenetically cryptic or complex insertion. The fusion oncoprotein represses the granulocytic differentiation program and disrupts PML nuclear-body functions, producing an expansion of abnormal promyelocytes. APL is both a hemorrhagic emergency and a highly curable malignancy when promptly recognized and treated with risk-adapted all-trans retinoic acid (ATRA), arsenic trioxide (ATO), and cytoreduction for high-risk disease according to the selected regimen.

Ask OpenScientist

Ask a research question about Acute Promyelocytic Leukemia, PML-RARA. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

13
Pathophys.
2
Histopath.
10
Phenotypes
1
Gaps
32
Pathograph
3
Genes
6
Medical Actions
1
Differentials
7
Trials
2
Models
29
References
2
Deep Research
🏷

Classifications

ICD-O Morphology
Leukemia
Harrison's Part
ONCOLOGY HEMATOLOGY
?

Discussions and Knowledge Gaps

1
Which cooperating somatic lesions determine progression from a PML::RARA-initiated preleukemic state to overt APL, and which of those lesions materially shape relapse or treatment resistance in humans?
KNOWLEDGE GAP OPEN gap_apl_cooperating_lesions
Attached to
pathophysiology#Somatic PML-RARA Fusion genetic#FLT3
PML::RARA transgenic mice show a long-latency, incompletely penetrant disease, whereas FLT3-ITD markedly accelerates an APL-like phenotype. This proves that cooperation can matter experimentally but does not establish a complete human progression or resistance map.
Show evidence (2 references)
PMID:9122233 SUPPORT Model Organism
"PMLRAR alpha transgenic mice exhibited impaired neutrophil maturation early in life, which progressed at a low frequency over the course of several months to overt APL."
Low-frequency, long-latency progression motivates the search for cooperating lesions.
PMID:12060771 SUPPORT Model Organism
"These observations document cooperation between PML/RARalpha and FLT3-ITD in development of the murine APL phenotype."
FLT3-ITD demonstrates one experimentally validated cooperation route.
⚙

Pathophysiology

13
Somatic PML-RARA Fusion
An acquired rearrangement fuses PML with RARA in a myeloid progenitor. Most cases have the classic t(15;17), but cryptic or complex insertions can generate the same fusion transcript without a visible classic translocation. PML::RARA is the initiating driver of this disease entry, while model studies show that additional events influence progression from a preleukemic state to overt leukemia.
promyelocyte CL:0000836 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves promyelocyte (CL:0000836). CL:0000836 is a cell type from the Cell Ontology.
PML hgnc:9113 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves PML (hgnc:9113). hgnc:9113 is a gene from the HUGO Gene Nomenclature Committee. RARA hgnc:9864 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves RARA (hgnc:9864). hgnc:9864 is a gene from the HUGO Gene Nomenclature Committee.
Downstream
PML-RARA Corepressor Recruitment PML::RARA binds response elements and recruits repressive chromatin machinery.
PML Nuclear-Body Disassembly PML::RARA antagonizes normal PML nuclear-body formation and function.
Show evidence (2 references)
PMID:24344243 SUPPORT Other
"Acute promyelocytic leukemia (APL) is a hematological malignancy driven by a chimeric oncoprotein containing the C terminus of the retinoic acid receptor-a (RARa) fused to an N-terminal partner, most commonly promyelocytic leukemia protein (PML)."
The review identifies PML-RARa as the driver oncoprotein in APL.
PMID:34193815 SUPPORT Other
"In about 10% of the cases, a successful cytogenetic analysis may lack classic t(15;17). In the majority of such cases, a molecular analysis nevertheless reveals an underlying PML–RARA fusion transcript formed as a result of cytogenetically cryptic or complex insertion events"
The review establishes that cryptic or complex events can produce PML-RARA without a visible classic translocation.
PML-RARA Corepressor Recruitment
PML::RARA binds retinoic-acid response elements and recruits DNA methyltransferases, histone deacetylases, and other corepressors, imposing a repressive chromatin state at differentiation-associated loci.
promyelocyte CL:0000836 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves promyelocyte (CL:0000836). CL:0000836 is a cell type from the Cell Ontology.
Downstream
Repression of the Granulocytic Differentiation Program Corepressor recruitment suppresses transcription of genes needed for granulocytic differentiation.
Show evidence (1 reference)
PMID:34193815 SUPPORT Other
"It binds to retinoic acid response elements of target genes and recruits co-repressors such as DNA methyltransferases and histone deacetylases"
The review describes the corepressor and chromatin-repressor complex recruited by PML::RARA.
Repression of the Granulocytic Differentiation Program
Repression of RARA-responsive and other myeloid genes prevents normal activation of the transcriptional program required for granulocyte maturation.
promyelocyte CL:0000836 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves promyelocyte (CL:0000836). CL:0000836 is a cell type from the Cell Ontology.
granulocyte differentiation GO:0030851 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased granulocyte differentiation (GO:0030851). GO:0030851 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Granulocytic Differentiation Arrest Failure to activate the granulocytic program arrests maturation near the promyelocyte stage.
Show evidence (1 reference)
PMID:16352814 SUPPORT In Vitro
"Here we found that conditional expression of promyelocytic leukemia-retinoic acid receptor alpha (PML-RARA), the protein encoded by the t(15;17) translocation found in acute promyelocytic leukemia (APL), suppressed PU.1 expression"
Conditional PML-RARA expression suppresses a key myeloid-differentiation transcription factor.
Granulocytic Differentiation Arrest
PML::RARA-expressing myeloid cells fail to complete neutrophil maturation, creating a preleukemic compartment from which overt APL can emerge.
promyelocyte CL:0000836 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves promyelocyte (CL:0000836). CL:0000836 is a cell type from the Cell Ontology.
neutrophil differentiation GO:0030223 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased neutrophil differentiation (GO:0030223). GO:0030223 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Promyelocyte Compartment Expansion Differentiation-arrested promyelocytes acquire increased proliferation and expand.
Show evidence (1 reference)
PMID:9122233 SUPPORT Model Organism
"PMLRAR alpha transgenic mice exhibited impaired neutrophil maturation early in life, which progressed at a low frequency over the course of several months to overt APL."
The transgenic model connects impaired maturation to a preleukemic state and later APL.
PML Nuclear-Body Disassembly
PML::RARA disrupts the formation and signaling functions of PML nuclear bodies, compromising the tumor-suppressive programs coordinated by PML.
promyelocyte CL:0000836 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves promyelocyte (CL:0000836). CL:0000836 is a cell type from the Cell Ontology.
PML body GO:0016605 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves PML body (GO:0016605). GO:0016605 is a cellular component from the Gene Ontology.
Downstream
Loss of PML-Mediated Senescence Nuclear-body dysfunction compromises PML-mediated senescence.
Show evidence (1 reference)
PMID:24344243 SUPPORT Other
"Mechanistically, PML-RARa acts as a transcriptional repressor of RARa and non-RARa target genes and antagonizes the formation and function of PML nuclear bodies that regulate numerous signaling pathways."
This directly supports PML nuclear-body disruption by the fusion oncoprotein.
Loss of PML-Mediated Senescence
Dominant-negative impairment of PML-mediated senescence permits persistence and transformation of fusion-expressing hematopoietic progenitors.
promyelocyte CL:0000836 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves promyelocyte (CL:0000836). CL:0000836 is a cell type from the Cell Ontology.
cellular senescence GO:0090398 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased cellular senescence (GO:0090398). GO:0090398 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Promyelocyte Compartment Expansion Failure of senescence permits persistence and expansion of the abnormal clone.
Show evidence (1 reference)
PMID:38503502 SUPPORT Other
"this simple (and sometimes sole) genetic alteration can transform hematopoietic progenitors through the acquisition of dominant-negative properties toward both transcriptional control by nuclear receptors and PML-mediated senescence"
This supports failure of PML-mediated senescence in fusion-driven transformation.
FLT3-ITD-Driven Proliferative Signaling
Activating FLT3 internal tandem duplication can provide a cooperating proliferative signal in PML::RARA-expressing hematopoietic cells. In the cited mouse model, the combination shortened leukemia latency and produced a fully penetrant APL-like disease; this node does not imply that FLT3-ITD is required in human APL.
hematopoietic cell CL:0000988 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves hematopoietic cell (CL:0000988). CL:0000988 is a cell type from the Cell Ontology.
FLT3 hgnc:3765 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves FLT3 (hgnc:3765). hgnc:3765 is a gene from the HUGO Gene Nomenclature Committee.
Downstream
Promyelocyte Compartment Expansion FLT3-ITD cooperates with PML::RARA to accelerate expansion into an APL-like disease.
Show evidence (1 reference)
PMID:12060771 SUPPORT In Vitro
"Activating mutations in FLT3, including internal tandem duplication (ITD) in the juxtamembrane domain, transform hematopoietic cell lines to factor independent growth."
The model paper identifies the proliferative effect of activating FLT3-ITD.
Promyelocyte Compartment Expansion
Morphologically abnormal, granule-rich promyelocytes expand in bone marrow and can appear in peripheral blood.
promyelocyte CL:0000836 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves promyelocyte (CL:0000836). CL:0000836 is a cell type from the Cell Ontology.
bone marrow UBERON:0002371 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in bone marrow (UBERON:0002371). UBERON:0002371 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Promyelocyte Procoagulant Activity Granule-associated tissue thromboplastin activity links abnormal promyelocytes to coagulation activation.
Bone marrow hypercellularity Expansion of abnormal promyelocytes is associated with a hypercellular marrow.
Suppression of Normal Hematopoiesis Marrow expansion of abnormal promyelocytes is inferred to suppress production of normal blood-cell lineages.
Show evidence (1 reference)
PMID:397771 SUPPORT Other
"Acute promyelocytic leukemia (APL) is characterized by proliferation of morphologically abnormal promyelocytes and a severe bleeding diathesis. The abnormal promyelocyte is characterized by abundant, large granules, many of which are spindle-shaped."
The overview describes the defining expansion and morphology of APL promyelocytes.
Suppression of Normal Hematopoiesis
Expansion of the leukemic promyelocyte compartment is inferred to impair normal marrow output, providing a common intermediate for multilineage cytopenias. Available evidence here establishes the clinical associations, so these links remain partial rather than asserted as directly proven.
bone marrow UBERON:0002371 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in bone marrow (UBERON:0002371). UBERON:0002371 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Pancytopenia Impaired normal marrow output manifests as reduction across multiple blood-cell lineages.
Anemia Impaired erythroid output is a plausible contributor to anemia in APL.
Thrombocytopenia Impaired megakaryopoiesis can contribute to thrombocytopenia alongside consumptive coagulopathy.
Leukopenia Impaired production of normal leukocyte lineages is a plausible contributor to leukopenia.
Show evidence (1 reference)
ORPHA:520 SUPPORT Other
"HP:0001876 | Pancytopenia | Frequent (79-30%)"
Frequent pancytopenia supports impaired multilineage marrow output as a plausible intermediate.
Promyelocyte Procoagulant Activity
Abnormal promyelocyte granules exhibit tissue thromboplastin activity, providing a direct route to systemic coagulation activation.
promyelocyte CL:0000836 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves promyelocyte (CL:0000836). CL:0000836 is a cell type from the Cell Ontology.
blood coagulation GO:0007596 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased blood coagulation (GO:0007596). GO:0007596 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Systemic Coagulation Activation and Consumptive Coagulopathy Promyelocyte-associated thromboplastin activity plausibly contributes to systemic coagulation activation and consumption.
Show evidence (1 reference)
PMID:397771 SUPPORT Other
"The granules appear to possess tissue thromboplastin activity by both immunologic and clotting assays."
This is direct biochemical evidence of promyelocyte-associated procoagulant activity.
Systemic Coagulation Activation and Consumptive Coagulopathy
APL produces a complex coagulopathy with clinically important hemorrhagic and thrombotic events. Consumptive coagulation is established, while modern reviews emphasize that the full hemostatic disturbance is broader than a single DIC mechanism.
blood coagulation GO:0007596 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal blood coagulation (GO:0007596). GO:0007596 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Disseminated Intravascular Coagulation Systemic coagulation activation manifests as disseminated intravascular coagulation.
Abnormal Bleeding Coagulation-factor and platelet consumption contribute to the severe bleeding diathesis.
Show evidence (2 references)
PMID:397771 SUPPORT Other
"Coagulation studies in APL are generally consistent with disseminated intravascular coagulation."
The source establishes the consumptive DIC pattern in APL.
PMID:37444587 SUPPORT Other
"However, there remains a considerable morbidity and mortality risk in APL secondary to clinically significant hemorrhagic and/or thrombotic events."
The updated review documents both hemorrhagic and thrombotic clinical consequences.
Differentiation Therapy-Induced Promyelocyte Maturation
During induction, ATRA and/or ATO drive rapid differentiation of leukemic blasts and promyelocytes. This therapeutic response can also initiate the cellular migration and endothelial signaling that precede differentiation syndrome.
promyelocyte CL:0000836 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves promyelocyte (CL:0000836). CL:0000836 is a cell type from the Cell Ontology.
neutrophil differentiation GO:0030223 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased neutrophil differentiation (GO:0030223). GO:0030223 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Differentiation Syndrome Inflammatory-Endothelial Response Differentiating cells migrate and activate endothelial and inflammatory signaling.
Show evidence (1 reference)
PMID:22220256 SUPPORT Other
"The differentiation of leukemic blasts and promyelocytes induced by ATRA and/or ATO may lead to cellular migration, endothelial activation, and release of interleukins and vascular factors responsible of tissue damage."
The review connects therapy-induced differentiation to the initiating events of differentiation syndrome.
Differentiation Syndrome Inflammatory-Endothelial Response
Cellular migration, endothelial activation, interleukin and vascular-factor release, tissue infiltration, and capillary leak contribute to differentiation syndrome. The relative contribution of these mechanisms remains incompletely resolved.
cytokine-mediated signaling pathway GO:0019221 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased cytokine-mediated signaling pathway (GO:0019221). GO:0019221 is a biological process from the Gene Ontology. ↑ INCREASED leukocyte migration GO:0050900 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased leukocyte migration (GO:0050900). GO:0050900 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Differentiation Syndrome The inflammatory-endothelial response produces the clinical differentiation syndrome.
Show evidence (1 reference)
PMID:22220256 SUPPORT Other
"The differentiation of leukemic blasts and promyelocytes induced by ATRA and/or ATO may lead to cellular migration, endothelial activation, and release of interleukins and vascular factors responsible of tissue damage."
The review supports a multi-component inflammatory and endothelial response rather than a cytokine-only model.
✶

Histopathology

2
Abnormal Granule-Rich Promyelocytes
Marrow and blood contain morphologically abnormal promyelocytes with abundant large granules, including spindle-shaped granules.
Show evidence (1 reference)
PMID:397771 SUPPORT Other
"Acute promyelocytic leukemia (APL) is characterized by proliferation of morphologically abnormal promyelocytes and a severe bleeding diathesis. The abnormal promyelocyte is characterized by abundant, large granules, many of which are spindle-shaped."
The complete snippet identifies both abnormal promyelocytes and their characteristic granules.
Characteristic Flow-Cytometric Immunophenotype
Classical APL commonly shows CD13, CD33, CD117, and HLA-DR negativity; variant patterns occur, so immunophenotyping supports rapid suspicion but does not replace molecular confirmation.
Show evidence (1 reference)
PMID:22535601 SUPPORT Human Clinical
"Leukemic cells had the following phenotype: CD11b-, CD11c-, CD13+, CD33+, CD45+, CD64+/-, CD117+, and HLA-DR-."
The 97-patient series defines the characteristic core immunophenotype while also documenting variants.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Acute Promyelocytic Leukemia, PML-RARA Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

10
Blood 6
Pancytopenia FREQUENT HP:0001876 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pancytopenia (HP:0001876). HP:0001876 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:520 SUPPORT Other
"HP:0001876 | Pancytopenia | Frequent (79-30%)"
Orphanet classifies pancytopenia as frequent.
Disseminated Intravascular Coagulation FREQUENT HP:0005521 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Disseminated intravascular coagulation (HP:0005521). HP:0005521 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:520 SUPPORT Other
"HP:0005521 | Disseminated intravascular coagulation | Frequent (79-30%)"
Orphanet classifies DIC as frequent.
Abnormal Bleeding FREQUENT HP:0001892 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal bleeding (HP:0001892). HP:0001892 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:520 SUPPORT Other
"HP:0001892 | Abnormal bleeding | Frequent (79-30%)"
Orphanet classifies abnormal bleeding as frequent.
Anemia FREQUENT HP:0001903 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Anemia (HP:0001903). HP:0001903 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:520 SUPPORT Other
"HP:0001903 | Anemia | Frequent (79-30%)"
Orphanet classifies anemia as frequent.
Thrombocytopenia FREQUENT HP:0001873 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Thrombocytopenia (HP:0001873). HP:0001873 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:520 SUPPORT Other
"HP:0001873 | Thrombocytopenia | Frequent (79-30%)"
Orphanet classifies thrombocytopenia as frequent.
Leukopenia FREQUENT Decreased total leukocyte count HP:0001882 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Leukopenia, annotated with Decreased total leukocyte count (HP:0001882). HP:0001882 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:520 SUPPORT Other
"HP:0001882 | Leukopenia | Frequent (79-30%)"
Orphanet classifies leukopenia as frequent.
Metabolism 1
Fever FREQUENT HP:0001945 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Fever (HP:0001945). HP:0001945 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:520 SUPPORT Other
"HP:0001945 | Fever | Frequent (79-30%)"
Orphanet classifies fever as frequent.
Constitutional 1
Fatigue FREQUENT HP:0012378 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Fatigue (HP:0012378). HP:0012378 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:520 SUPPORT Other
"HP:0012378 | Fatigue | Frequent (79-30%)"
Orphanet classifies fatigue as frequent.
Other 2
Bone marrow hypercellularity FREQUENT HP:0031020 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Bone marrow hypercellularity (HP:0031020). HP:0031020 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:520 SUPPORT Other
"HP:0031020 | Bone marrow hypercellularity | Frequent (79-30%)"
Orphanet classifies bone marrow hypercellularity as frequent.
Differentiation Syndrome
Show evidence (1 reference)
PMID:24627526 SUPPORT Other
"The full-blown syndrome consists of unexplained fever, weight gain, dyspnea with pulmonary infiltrates, pleuropericardial effusion, hypotension, and renal failure."
The review defines the clinical syndrome without assigning a universal frequency.
🧬

Genetic Associations

3
PML Fusion Partner (5-prime partner in the defining somatic PML::RARA fusion driver)
Gene: PML hgnc:9113 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is PML (hgnc:9113). hgnc:9113 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC
Show evidence (3 references)
PMID:39858554 SUPPORT Human Clinical
"Acute promyelocytic leukemia (APL) is characterized by abnormal promyelocytes and t(15;17)(q24;q21) PML::RARA."
The clinical review identifies PML as a partner in the defining fusion.
PMID:9122233 SUPPORT Model Organism
"Our results demonstrate that PMLRAR alpha impairs neutrophil differentiation and initiates the development of APL."
The transgenic model supports an initiating-driver relationship.
PMID:12060771 SUPPORT Model Organism
"Expression of PML/RARalpha from the cathepsin G promoter in transgenic mice causes a nonfatal myeloproliferative syndrome in all mice; about 15% go on to develop APL after a long latent period, suggesting that additional mutations are required for the development of APL."
The model directly supports long latency, incomplete penetrance, and the need for cooperating events.
RARA Fusion Partner (3-prime partner in the defining somatic PML::RARA fusion driver)
Gene: RARA hgnc:9864 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is RARA (hgnc:9864). hgnc:9864 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC
Show evidence (1 reference)
PMID:39858554 SUPPORT Human Clinical
"Acute promyelocytic leukemia (APL) is characterized by abnormal promyelocytes and t(15;17)(q24;q21) PML::RARA."
The clinical review identifies RARA as a partner in the defining fusion.
FLT3 (Cooperating somatic alteration and prognostic biomarker)
Gene: FLT3 hgnc:3765 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is FLT3 (hgnc:3765). hgnc:3765 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: COOPERATING variant_origin: SOMATIC
Show evidence (2 references)
PMID:12060771 SUPPORT Model Organism
"These observations document cooperation between PML/RARalpha and FLT3-ITD in development of the murine APL phenotype."
The model directly demonstrates functional cooperation.
PMID:36539954 SUPPORT Human Clinical
"FLT3-ITD was an independent adverse factor for 5-year PFS, and ACA was an independent adverse factor for 5-year OS."
The human cohort supports a prognostic association without establishing a treatment rule.
💊

Medical Actions

6
Immediate All-Trans Retinoic Acid (ATRA)
Category: Therapeutic Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: all-trans-retinoic acid CHEBI:15367 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses all-trans-retinoic acid (CHEBI:15367). CHEBI:15367 is a therapeutic agent from Chemical Entities of Biological Interest.
ATRA should begin at the first clinical suspicion of APL while confirmatory testing proceeds. It releases PML::RARA-associated corepressors and restores terminal myeloid differentiation.
Mechanism Target:
INHIBITS PML-RARA Corepressor Recruitment — Ligand binding releases corepressors and relieves fusion-mediated transcriptional repression.
Show evidence (1 reference)
PMID:34193815 SUPPORT Other
"ATRA causes a conformational change of the PML–RARA fusion transcripts, leading to the release of the co-repressors, recruitment of histone acetyltransferases, and relief of transcriptional repression"
The review directly supports the ATRA target mechanism.
ACTIVATES Differentiation Therapy-Induced Promyelocyte Maturation — ATRA induces differentiation of leukemic blasts and promyelocytes.
Show evidence (1 reference)
PMID:22220256 SUPPORT Other
"The differentiation of leukemic blasts and promyelocytes induced by ATRA and/or ATO may lead to cellular migration, endothelial activation, and release of interleukins and vascular factors responsible of tissue damage."
The review directly identifies ATRA-induced promyelocyte differentiation.
Show evidence (1 reference)
PMID:34193815 SUPPORT Other
"Immediate administration of ATRA at the first suspicion of APL diagnosis is of extreme importance."
The review supports immediate empiric initiation without asserting an unsupported universal dose.
Arsenic Trioxide (ATO)
Category: Therapeutic Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: arsenic trioxide CHEBI:30621 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses arsenic trioxide, annotated with diarsenic trioxide (CHEBI:30621). CHEBI:30621 is a therapeutic agent from Chemical Entities of Biological Interest.
ATO targets PML/PML::RARA, promotes fusion-protein degradation, and restores PML nuclear-body architecture.
Mechanism Target:
INHIBITS PML Nuclear-Body Disassembly — ATO drives PML::RARA degradation and PML nuclear-body reformation.
Show evidence (1 reference)
PMID:37655965 SUPPORT In Vitro
"Arsenic trioxide (ATO) cures 70% of patients with APL, driving PML-RARA degradation and NB reformation."
The mechanistic study directly supports degradation and nuclear-body reformation.
ACTIVATES Differentiation Therapy-Induced Promyelocyte Maturation — ATO induces differentiation of leukemic blasts and promyelocytes.
Show evidence (1 reference)
PMID:22220256 SUPPORT Other
"The differentiation of leukemic blasts and promyelocytes induced by ATRA and/or ATO may lead to cellular migration, endothelial activation, and release of interleukins and vascular factors responsible of tissue damage."
The review directly identifies ATO-induced promyelocyte differentiation.
Show evidence (1 reference)
PMID:37655965 SUPPORT In Vitro
"Arsenic curative effects in APL rely on PML targeting."
The study identifies PML targeting as central to ATO efficacy.
ATRA plus ATO for Non-High-Risk APL
Category: Therapeutic Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986 Regimen: Arsenic Trioxide/Tretinoin RegimenNCI Thesaurus (NCIT) Relation: this regimen component is this clinical intervention This regimen component is Arsenic Trioxide/Tretinoin Regimen (NCIT:C198431). NCIT:C198431 is a clinical intervention from the NCI Thesaurus. NCIT:C198431
Agent: all-trans-retinoic acid CHEBI:15367 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses all-trans-retinoic acid (CHEBI:15367). CHEBI:15367 is a therapeutic agent from Chemical Entities of Biological Interest. arsenic trioxide CHEBI:30621 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses arsenic trioxide, annotated with diarsenic trioxide (CHEBI:30621). CHEBI:30621 is a therapeutic agent from Chemical Entities of Biological Interest.
For newly diagnosed non-high-risk APL (presenting white-cell count at or below 10 × 10^9/L), ATRA plus ATO is a chemotherapy-free induction and consolidation strategy supported by randomized phase III evidence.
Mechanism Target:
INHIBITS PML-RARA Corepressor Recruitment — The ATRA component relieves PML::RARA-mediated transcriptional repression.
Show evidence (1 reference)
PMID:34193815 SUPPORT Other
"ATRA causes a conformational change of the PML–RARA fusion transcripts, leading to the release of the co-repressors, recruitment of histone acetyltransferases, and relief of transcriptional repression"
This supports the ATRA component's target mechanism.
INHIBITS PML Nuclear-Body Disassembly — The ATO component promotes PML::RARA degradation and nuclear-body reformation.
Show evidence (1 reference)
PMID:37655965 SUPPORT In Vitro
"Arsenic trioxide (ATO) cures 70% of patients with APL, driving PML-RARA degradation and NB reformation."
This supports the ATO component's target mechanism.
Show evidence (1 reference)
PMID:23841729 SUPPORT Human Clinical
"CONCLUSIONS: ATRA plus arsenic trioxide is at least not inferior and may be superior to ATRA plus chemotherapy in the treatment of patients with low-to-intermediate-risk APL."
The randomized phase III trial supports the regimen specifically in low-to-intermediate-risk APL.
ATRA plus ATO and Limited Idarubicin for High-Risk APL
Category: Therapeutic Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986 Regimen: Arsenic Trioxide/Idarubicin/Tretinoin RegimenNCI Thesaurus (NCIT) Relation: this regimen component is this clinical intervention This regimen component is Arsenic Trioxide/Idarubicin/Tretinoin Regimen (NCIT:C198433). NCIT:C198433 is a clinical intervention from the NCI Thesaurus. NCIT:C198433
Agent: all-trans-retinoic acid CHEBI:15367 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses all-trans-retinoic acid (CHEBI:15367). CHEBI:15367 is a therapeutic agent from Chemical Entities of Biological Interest. arsenic trioxide CHEBI:30621 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses arsenic trioxide, annotated with diarsenic trioxide (CHEBI:30621). CHEBI:30621 is a therapeutic agent from Chemical Entities of Biological Interest. idarubicin CHEBI:42068 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses idarubicin (CHEBI:42068). CHEBI:42068 is a therapeutic agent from Chemical Entities of Biological Interest.
For newly diagnosed high-risk APL (presenting white-cell count above 10 × 10^9/L), APOLLO paired ATRA plus ATO with two idarubicin doses and improved two-year event-free survival relative to its anthracycline-based comparator; this is not a chemotherapy-free regimen. The 133-patient trial stopped early because of slow accrual during the COVID-19 pandemic, which limits precision.
Mechanism Target:
INHIBITS PML-RARA Corepressor Recruitment — ATRA relieves PML::RARA-mediated repression.
Show evidence (1 reference)
PMID:34193815 SUPPORT Other
"ATRA causes a conformational change of the PML–RARA fusion transcripts, leading to the release of the co-repressors, recruitment of histone acetyltransferases, and relief of transcriptional repression"
This supports the ATRA component's mechanism.
INHIBITS PML Nuclear-Body Disassembly — ATO promotes PML::RARA degradation and nuclear-body reformation.
Show evidence (1 reference)
PMID:37655965 SUPPORT In Vitro
"Arsenic trioxide (ATO) cures 70% of patients with APL, driving PML-RARA degradation and NB reformation."
This supports the ATO component's mechanism.
Show evidence (4 references)
PMID:34193815 SUPPORT Other
"A presentation WBC count greater than 10,000/µL represents high-risk APL."
The treatment review defines the high-risk white-cell-count threshold used here.
PMID:40825164 SUPPORT Human Clinical
"Adult patients with newly diagnosed high-risk APL in the ATRA-ATO arm received ATO 0.15 mg/kg once daily and ATRA 45 mg/m2 twice daily until complete remission (CR), with two doses of idarubicin 12 mg/m2 on days 1 and 3, followed by consolidation therapy (four ATRA-ATO cycles)."
The trial methods establish the ATRA-ATO strategy with limited idarubicin in high-risk APL.
PMID:40825164 SUPPORT Human Clinical
"After a median follow-up of 37 months (range, 1.7-88.6 months), 2-year EFS was 88% in the ATRA-ATO arm and 71% in the ATRA-CHT arm"
The trial directly supports the reported event-free-survival advantage.
+ 1 more reference
Transfusion Support for APL Coagulopathy
Category: Therapeutic Action: Supportive CareNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Supportive Care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. NCIT:C15747
Begin blood-product support immediately when APL is suspected, alongside ATRA, and monitor platelets and coagulation parameters frequently during induction. Replace platelets, fibrinogen, and other coagulation factors to reduce bleeding risk. Targets vary among protocols; one published algorithm uses INR below 1.5-2.0, fibrinogen above 100 mg/dL, and platelets above 30,000/µL rather than establishing a universal threshold for all settings.
Target Phenotypes: Abnormal Bleeding HP:0001892 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Abnormal Bleeding (HP:0001892). HP:0001892 is a phenotype from the Human Phenotype Ontology. Thrombocytopenia HP:0001873 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Thrombocytopenia (HP:0001873). HP:0001873 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:34193815 SUPPORT Other
"In addition to prompt ATRA administration, coagulopathy should be adequately corrected by keeping internationalized normalized ratio (INR) for PT at less than 1.5–2.0, fibrinogen greater than 100 mg/dL platelets greater than 30,000/µL through blood product transfusions."
The review supports immediate correction alongside ATRA and gives one explicit protocol's targets.
PMID:34193815 SUPPORT Other
"Platelet counts and coagulation parameters, including PTT, PT, as well as fibrinogen levels, should be monitored daily to keep these parameters within range."
The review supports frequent laboratory monitoring during correction of APL coagulopathy.
PMID:33860520 SUPPORT Other
"Other aspects of management focus on supportive care aimed at minimizing the risk of bleeding, via transfusion of blood products."
The review supports transfusion-based supportive care while avoiding unsupported universal thresholds.
Dexamethasone for Differentiation Syndrome
Category: Therapeutic Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
Agent: dexamethasone CHEBI:41879 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses dexamethasone (CHEBI:41879). CHEBI:41879 is a therapeutic agent from Chemical Entities of Biological Interest.
Dexamethasone should be started promptly when differentiation syndrome is suspected; one treatment review recommends 10 mg every 12 hours until signs resolve or for at least three days. Holding ATRA or ATO is generally reserved for severe clinical deterioration rather than routine management.
Mechanism Target:
INHIBITS Differentiation Syndrome Inflammatory-Endothelial Response — Corticosteroid therapy suppresses the inflammatory response associated with the syndrome.
Show evidence (1 reference)
PMID:24627526 SUPPORT Other
"DS diagnosis should be suspected in the presence of any of the above-mentioned signs and symptoms, and preemptive treatment with dexamethasone should be started immediately."
The review supports immediate dexamethasone treatment; the precise molecular target is inferred from corticosteroid action.
Show evidence (3 references)
PMID:34193815 SUPPORT Other
"Dexamethasone 10 mg (every 12 hours) should be administered for the treatment of suspected or overt DS, until resolution of symptoms and signs or for a minimum of three days"
The treatment review supports the stated dexamethasone schedule.
PMID:24627526 SUPPORT Other
"DS diagnosis should be suspected in the presence of any of the above-mentioned signs and symptoms, and preemptive treatment with dexamethasone should be started immediately."
The review directly supports prompt dexamethasone at clinical suspicion.
PMID:24627526 SUPPORT Other
"Temporary discontinuation of all-trans retinoic acid or arsenic trioxide is indicated only for patients in very poor clinical condition or with severe renal or pulmonary dysfunction, sometimes requiring admission to the intensive care unit."
The review limits temporary interruption of differentiating agents to severe clinical deterioration.
🔬

Biochemical Markers

2
Consumptive Coagulation Profile
Pathograph Readouts
Readout Of Systemic Coagulation Activation and Consumptive Coagulopathy Threshold Dependent Monitoring
The combined coagulation profile reflects the severity and evolution of APL coagulopathy.
Show evidence (1 reference)
PMID:34193815 SUPPORT Other
"A consumptive coagulopathy consisting of elevated partial thromboplastin time (PTT), prothrombin time (PT), and D-dimers, together with hypofibrinogenemia, and thrombocytopenia is another common feature present in three-quarters of the patients at diagnosis [15]."
The measured profile is a readout of the consumptive coagulopathy node.
Show evidence (1 reference)
PMID:34193815 SUPPORT Other
"A consumptive coagulopathy consisting of elevated partial thromboplastin time (PTT), prothrombin time (PT), and D-dimers, together with hypofibrinogenemia, and thrombocytopenia is another common feature present in three-quarters of the patients at diagnosis [15]."
The review supports the listed coagulation abnormalities and their common occurrence at diagnosis.
PML-RARA Fusion Transcript
Pathograph Readouts
Readout Of Somatic PML-RARA Fusion Present Absent Diagnostic
Detection of the fusion transcript confirms the molecular lesion represented by the root node.
Show evidence (1 reference)
DOI:10.3390/cancers16061160 SUPPORT Other
"The hallmark of acute promyelocytic leukemia (APL) is the presence of the characteristic fusion transcript of the promyelocytic leukemia gene with the retinoic acid receptor α gene (PML::RARA)."
Presence of the transcript directly reports the fusion lesion.
Correlates With Promyelocyte Compartment Expansion Positive Monitoring
End-of-consolidation molecular response and subsequent PML::RARA PCR monitoring report residual or recurrent leukemic burden.
Show evidence (2 references)
DOI:10.3390/cancers16183208 SUPPORT Other
"Acute promyelocytic leukemia (APL) leads the way in this transformation, initially using PCR to detect MRD in patients in remission, and more recently, aiming to eliminate it entirely with modern treatment strategies."
The review supports PCR-based monitoring of residual disease in APL remission.
PMID:34193815 SUPPORT Other
"Maintenance therapy is not part of our standard practice for patients who achieve molecular CR at the end of consolidation with ATRA plus ATO based regimens."
The treatment review identifies molecular complete remission at the end of consolidation as a defined response milestone.
Show evidence (1 reference)
DOI:10.3390/cancers16061160 SUPPORT Other
"The hallmark of acute promyelocytic leukemia (APL) is the presence of the characteristic fusion transcript of the promyelocytic leukemia gene with the retinoic acid receptor α gene (PML::RARA)."
The review identifies the fusion transcript as the molecular hallmark.
🔬

Diagnosis

3
Morphologic Suspicion of APL
Peripheral blood and marrow morphology showing abnormal promyelocytes with irregular azurophilic granules or Auer rods should trigger urgent evaluation and empiric ATRA while molecular confirmation is pursued.
Show evidence (2 references)
PMID:34193815 SUPPORT Other
"Microscopic identification of circulating promyelocytes with irregular azurophilic granules or Auer rods strongly supports APL diagnosis."
The review identifies the morphology that strongly supports rapid suspicion.
PMID:34193815 SUPPORT Other
"Immediate administration of ATRA at the first suspicion of APL diagnosis is of extreme importance."
The review directly supports empiric ATRA at morphologic suspicion while confirmation is pursued.
Molecular Confirmation of PML::RARA
Confirm the PML::RARA fusion by molecular testing. A negative conventional karyotype does not exclude cryptic or complex rearrangements, so RT-PCR or another sensitive molecular method is important when morphology remains compelling.
Results: PML::RARA fusion transcript detected
Show evidence (2 references)
PMID:34193815 SUPPORT Other
"In the majority of such cases, a molecular analysis nevertheless reveals an underlying PML–RARA fusion transcript formed as a result of cytogenetically cryptic or complex insertion events [2]."
The review supports molecular detection when classic cytogenetic findings are absent.
PMID:39858554 SUPPORT Human Clinical
"RT-PCR revealed a cryptic PML::RARA fusion transcript."
A cryptic clinical case demonstrates the value of RT-PCR confirmation.
Supportive Flow-Cytometric Immunophenotyping
Flow cytometry can rapidly identify a characteristic APL pattern and prioritize confirmatory fusion testing, but variant immunophenotypes prevent it from being a stand-alone molecular diagnosis.
Markers: CD13+, CD33+, CD117+, HLA-DR- with variant patterns
Show evidence (1 reference)
PMID:22535601 SUPPORT Human Clinical
"Apart from a well-known FC pattern of hypergranular APL, we presented less common immunophenotypic variants of APL, which helps to identify an additional group of patients who would benefit from fast confirmatory FISH and/or PCR testing for t(15;17)/PML-RARA."
The study supports flow cytometry as a triage tool for rapid confirmatory testing.
📈

Progression

3
Early hemorrhagic-risk presentation
Newly suspected APL is an urgent condition requiring prompt recognition to avoid early mortality; a severe bleeding diathesis can already be present at presentation.
Show evidence (2 references)
PMID:38890097 SUPPORT Other
"Finally, acute promyelocytic leukemia is presented as a highly curable disease because of the real possibility of targeted therapy towards differentiation, and, paradoxically, as a serious and urgent condition that deserves prompt recognition and management to avoid early mortality."
The current consensus identifies the urgent early-mortality phase.
PMID:397771 SUPPORT Other
"Acute promyelocytic leukemia (APL) is characterized by proliferation of morphologically abnormal promyelocytes and a severe bleeding diathesis."
The review directly supports the severe bleeding risk present with APL.
Induction and differentiation-syndrome window
Differentiation syndrome occurs during induction with ATRA and/or ATO and requires prompt recognition; the mechanism includes differentiating-cell migration, endothelial activation, and vascular leak.
Show evidence (1 reference)
PMID:22220256 SUPPORT Other
"Roughly one quarter of patients with APL undergoing induction therapy will develop the DS, characterized by unexplained fever, acute respiratory distress with interstitial pulmonary infiltrates, and/or a vascular capillary leak syndrome leading to acute renal failure."
The review places differentiation syndrome in the induction phase.
End-of-consolidation molecular response and follow-up
Molecular complete remission at the end of consolidation is the key response milestone represented here. Thereafter, PML::RARA PCR can detect residual or recurrent molecular disease during risk-adapted follow-up.
Show evidence (2 references)
PMID:34193815 SUPPORT Other
"Maintenance therapy is not part of our standard practice for patients who achieve molecular CR at the end of consolidation with ATRA plus ATO based regimens."
The treatment review identifies end-of-consolidation molecular complete remission as a response milestone.
DOI:10.3390/cancers16183208 SUPPORT Other
"Acute promyelocytic leukemia (APL) leads the way in this transformation, initially using PCR to detect MRD in patients in remission, and more recently, aiming to eliminate it entirely with modern treatment strategies."
The review supports PCR-based monitoring after the defined molecular-response milestone.
📊

Prevalence

1
Europe
Annual Incidence 0.1–0.9 per 100,000 1–9 per 1,000,000
Orphanet reports an annual incidence band of 1-9 per 1,000,000 in Europe. This is an incidence estimate, not a point-prevalence estimate or the fraction of acute myeloid leukemia cases represented by APL.
Show evidence (1 reference)
ORPHA:520 SUPPORT Other
"1-9 / 1 000 000 | Europe | Annual incidence | REG"
Orphanet provides the European annual-incidence band.
🔀

Differential Diagnoses

1

Conditions with similar clinical presentations that must be differentiated from Acute Promyelocytic Leukemia, PML-RARA:

APL-Like Acute Myeloid Leukemia Without PML::RARA
Overlapping Features A small, genetically heterogeneous group of AMLs can show APL-like morphology or immunophenotype without t(15;17). Molecular confirmation is decisive because these entities differ in genetics, therapy sensitivity, and prognosis.
Distinguishing Features
  • Absence of the defining PML::RARA fusion
  • Alternative genetic lesion on expanded molecular testing
  • Therapy response may differ from PML::RARA-positive APL
Show evidence (1 reference)
DOI:10.3390/cancers16244192 SUPPORT Other
"However, a small percentage (estimated to be 2%) of AML presenting with APL-like morphology and/or immunophenotype lacks t(15;17)."
The review directly identifies the molecularly distinct APL-like differential group.
🔬

Clinical Trials

7
NCT00482833 PHASE_III COMPLETED
APL0406 randomized low-to-intermediate-risk APL to ATRA plus ATO versus ATRA plus idarubicin-based chemotherapy and established the chemotherapy-free regimen's noninferiority, with superior event-free survival in the reported analysis.
Show evidence (3 references)
PMID:23841729 SUPPORT Human Clinical
"We conducted a phase 3, multicenter trial comparing ATRA plus chemotherapy with ATRA plus arsenic trioxide in patients with APL classified as low-to-intermediate risk (white-cell count, ≤10×10(9) per liter)."
The publication defines the completed phase III trial population and comparison.
PMID:23841729 SUPPORT Human Clinical
"Two-year event-free survival rates were 97% in the ATRA-arsenic trioxide group and 86% in the ATRA-chemotherapy group"
The publication directly supports the superior event-free survival stated in the trial summary.
PMID:23841729 SUPPORT Human Clinical
"ClinicalTrials.gov number, NCT00482833."
The publication explicitly identifies ClinicalTrials.gov record NCT00482833.
NCT02688140 PHASE_III COMPLETED
APOLLO compared ATRA plus ATO with limited idarubicin against standard ATRA-anthracycline therapy in newly diagnosed high-risk APL.
Show evidence (2 references)
PMID:40825164 SUPPORT Human Clinical
"PURPOSE: The phase III APOLLO trial prospectively compared the efficacy of arsenic trioxide (ATO) in combination with all-trans retinoic acid (ATRA)"
The publication identifies APOLLO as a phase III comparison of the ATRA-ATO strategy.
PMID:40825164 SUPPORT Human Clinical
"plus low-dose idarubicin versus standard ATRA plus anthracycline-based chemotherapy (ATRA-CHT) regimen (ie, ATRA and idarubicin regimen) in patients with high-risk acute promyelocytic leukemia (APL; EudraCT 2015-01151-68; ClinicalTrials.gov identifier: NCT02688140)."
The publication supplies the comparator, high-risk population, and ClinicalTrials.gov identifier.
NCT07503730 PHASE_III RECRUITING
Multicenter randomized study testing whether adding oral Realgar-Indigo Naturalis Formula to immediate ATRA before molecular confirmation reduces 30-day early mortality in suspected APL.
Show evidence (3 references)
clinicaltrials:NCT07503730 SUPPORT Human Clinical
"This multicenter, randomized controlled trial evaluates whether early induction treatment with oral Realgar-Indigo Naturalis Formula (RIF) combined with all-trans retinoic acid (ATRA) reduces early death rates in patients with acute promyelocytic leukemia (APL)."
The current registry record supports the randomized early-intervention design and disease population.
clinicaltrials:NCT07503730 SUPPORT Human Clinical
"Experimental group: oral ATRA + RIF before molecular diagnosis confirmation"
The registry directly supports starting the experimental combination before molecular confirmation.
clinicaltrials:NCT07503730 SUPPORT Human Clinical
"To evaluate whether early induction with ATRA + RIF reduces early death rate (within 30 days of diagnosis) in APL patients."
The registry directly supports the 30-day early-mortality endpoint.
NCT07296445 PHASE_III NOT_RECRUITING
LATITUDE is a randomized crossover study of oral versus intravenous arsenic trioxide during consolidation for newly diagnosed non-high-risk APL.
Show evidence (1 reference)
clinicaltrials:NCT07296445 SUPPORT Human Clinical
"LATITUDE: A Phase 3, Randomized, Open-Label, 3-Cohort, 2-Period, 2-Sequence, Crossover Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of Oral Arsenic Trioxide Versus Intravenous Arsenic Trioxide for Consolidation Therapy in Participants With Newly Diagnosed, Non-High Risk, Acute..."
The current registry record supports the phase III oral-versus-intravenous consolidation comparison.
NCT01409161 PHASE_II RECRUITING
Phase II study of ATRA plus ATO with or without gemtuzumab ozogamicin in previously untreated APL.
Show evidence (1 reference)
clinicaltrials:NCT01409161 SUPPORT Human Clinical
"This phase II trial studies how well tretinoin and arsenic trioxide with or without gemtuzumab ozogamicin works in treating patients with previously untreated acute promyelocytic leukemia."
The current registry record supports the phase II regimen and untreated-APL population.
NCT06982274 PHASE_II RECRUITING
International Consortium on APL study of oral arsenic plus ATRA, adding minimal-dose chemotherapy for high-risk newly diagnosed disease.
Show evidence (1 reference)
clinicaltrials:NCT06982274 SUPPORT Human Clinical
"It is a non-randomized, multicenter, prospective study, aiming to treat patients with newly diagnosed acute promyelocytic leukemia with a combination of oral arsenic and atra, with low dose chemotherapy for those with high-risk disease (white blood cell count above 10x10a9/L)."
The current registry record supports the oral-arsenic strategy and risk-adapted chemotherapy component.
NCT07187505 NOT_APPLICABLE ACTIVE_NOT_RECRUITING
Prospective single-arm study of venetoclax added to ATRA and ATO for newly diagnosed APL with hyperleukocytosis.
Show evidence (1 reference)
clinicaltrials:NCT07187505 SUPPORT Human Clinical
"This study aims to evaluate the safety and effectiveness of combining venetoclax with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) in patients with newly diagnosed acute promyelocytic leukemia (APL) who have very high white blood cell counts."
The current registry record supports the hyperleukocytic-APL combination study.
🐁

Animal Models

2
Myeloid-cell PMLRARalpha transgenic mouse Mus musculus
Myeloid expression of PMLRARalpha produces early impaired neutrophil maturation, a transplantable preleukemic state, and low-frequency, long-latency APL that remains retinoic-acid responsive. The model separates fusion-driven initiation from the additional events required for efficient progression.
Impaired neutrophil maturation Preleukemic promyelocyte expansion Retinoic-acid-responsive APL
Species
Mus musculus
Genotype
Myeloid-cell PMLRARalpha transgenic mouse
Genes
PML hgnc:9113 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns PML (hgnc:9113). hgnc:9113 is a gene from the HUGO Gene Nomenclature Committee. RARA hgnc:9864 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns RARA (hgnc:9864). hgnc:9864 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (3 references)
PMID:9122233 SUPPORT Model Organism
"PMLRAR alpha transgenic mice exhibited impaired neutrophil maturation early in life, which progressed at a low frequency over the course of several months to overt APL."
The model reproduces the maturation defect and low-frequency progression to overt leukemia.
PMID:9122233 SUPPORT Model Organism
"Both the preleukemic state and the leukemia could be transplanted to nontransgenic mice, and the transplanted preleukemia could progress to APL."
The experiment directly supports transplantability of both the preleukemic and leukemic states.
PMID:9122233 SUPPORT Model Organism
"The APL recapitulated features of the human disease, including a response to retinoic acid. Retinoic acid caused the leukemic cells to differentiate in vitro and in vivo, eliciting remissions of both the preleukemic state and APL in mice."
The model directly supports retinoic-acid responsiveness and remission.
PML/RARalpha transgenic marrow with retroviral FLT3-ITD Mus musculus
FLT3-ITD transduction of marrow from PML/RARalpha transgenic mice yields a short-latency, fully penetrant, transplantable, ATRA-responsive APL-like disease, directly testing genetic cooperation.
Short-latency APL-like leukemia Transplantable leukemia ATRA responsiveness
Species
Mus musculus
Genotype
PML/RARalpha transgenic marrow with retroviral FLT3-ITD
Genes
PML hgnc:9113 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns PML (hgnc:9113). hgnc:9113 is a gene from the HUGO Gene Nomenclature Committee. RARA hgnc:9864 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns RARA (hgnc:9864). hgnc:9864 is a gene from the HUGO Gene Nomenclature Committee. FLT3 hgnc:3765 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns FLT3 (hgnc:3765). hgnc:3765 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (2 references)
PMID:12060771 SUPPORT Model Organism
"Retroviral transduction of FLT3-ITD into bone marrow cells obtained from PML/RARalpha transgenic mice results in a short latency APL-like disease with complete penetrance."
The experiment directly demonstrates rapid, penetrant disease after combining the two lesions.
PMID:12060771 SUPPORT Model Organism
"The leukemia is transplantable to secondary recipients and is ATRA responsive."
The experiment directly supports the two additional model properties stated in the description.
{ }

Source YAML

click to show 
name: Acute Promyelocytic Leukemia, PML-RARA
creation_date: '2026-01-26T02:55:13Z'
description: >-
  Acute promyelocytic leukemia (APL) with PML::RARA is a molecularly defined
  acute myeloid leukemia caused by a somatic PML::RARA rearrangement, most often
  the classic t(15;17) but sometimes a cytogenetically cryptic or complex
  insertion. The fusion oncoprotein represses the granulocytic differentiation
  program and disrupts PML nuclear-body functions, producing an expansion of
  abnormal promyelocytes. APL is both a hemorrhagic emergency and a highly
  curable malignancy when promptly recognized and treated with risk-adapted
  all-trans retinoic acid (ATRA), arsenic trioxide (ATO), and cytoreduction for
  high-risk disease according to the selected regimen.
categories:
- Hematologic Malignancy
- Acute Leukemia
- Molecularly Defined Cancer
parents:
- acute myeloid leukemia

prevalence:
- population: Europe
  measure_type: ANNUAL_INCIDENCE
  prevalence_class: BAND_1_9_PER_1000000
  rate_low: 0.1
  rate_high: 0.9
  notes: >-
    Orphanet reports an annual incidence band of 1-9 per 1,000,000 in Europe.
    This is an incidence estimate, not a point-prevalence estimate or the
    fraction of acute myeloid leukemia cases represented by APL.
  evidence:
  - reference: ORPHA:520
    reference_title: Acute promyelocytic leukemia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 1 000 000 | Europe | Annual incidence | REG"
    explanation: Orphanet provides the European annual-incidence band.

pathophysiology:
- name: Somatic PML-RARA Fusion
  description: >-
    An acquired rearrangement fuses PML with RARA in a myeloid progenitor. Most
    cases have the classic t(15;17), but cryptic or complex insertions can
    generate the same fusion transcript without a visible classic
    translocation. PML::RARA is the initiating driver of this disease entry,
    while model studies show that additional events influence progression from
    a preleukemic state to overt leukemia.
  genes:
  - preferred_term: PML
    term:
      id: hgnc:9113
      label: PML
  - preferred_term: RARA
    term:
      id: hgnc:9864
      label: RARA
  cell_types:
  - preferred_term: promyelocyte
    term:
      id: CL:0000836
      label: promyelocyte
  evidence:
  - reference: PMID:24344243
    reference_title: "Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Acute promyelocytic leukemia (APL) is a hematological malignancy driven by
      a chimeric oncoprotein containing the C terminus of the retinoic acid
      receptor-a (RARa) fused to an N-terminal partner, most commonly
      promyelocytic leukemia protein (PML).
    explanation: The review identifies PML-RARa as the driver oncoprotein in APL.
  - reference: PMID:34193815
    reference_title: Acute promyelocytic leukemia current treatment algorithms.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In about 10% of the cases, a successful cytogenetic analysis may lack
      classic t(15;17). In the majority of such cases, a molecular analysis
      nevertheless reveals an underlying PML–RARA fusion transcript formed as a
      result of cytogenetically cryptic or complex insertion events
    explanation: The review establishes that cryptic or complex events can produce PML-RARA without a visible classic translocation.
  downstream:
  - target: PML-RARA Corepressor Recruitment
    description: PML::RARA binds response elements and recruits repressive chromatin machinery.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:34193815
      reference_title: Acute promyelocytic leukemia current treatment algorithms.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        It binds to retinoic acid response elements of target genes and recruits
        co-repressors such as DNA methyltransferases and histone deacetylases,
        and sequesters retinoic X receptor and the wild-type PML protein, which
        finally leads to suppression of genes necessary for granulocytic
        differentiation
      explanation: This directly supports fusion-protein recruitment of corepressors.
  - target: PML Nuclear-Body Disassembly
    description: PML::RARA antagonizes normal PML nuclear-body formation and function.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24344243
      reference_title: "Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Mechanistically, PML-RARa acts as a transcriptional repressor of RARa and
        non-RARa target genes and antagonizes the formation and function of PML
        nuclear bodies that regulate numerous signaling pathways.
      explanation: The review directly attributes loss of PML nuclear-body formation and function to PML-RARa.

- name: PML-RARA Corepressor Recruitment
  description: >-
    PML::RARA binds retinoic-acid response elements and recruits DNA
    methyltransferases, histone deacetylases, and other corepressors, imposing a
    repressive chromatin state at differentiation-associated loci.
  cell_types:
  - preferred_term: promyelocyte
    term:
      id: CL:0000836
      label: promyelocyte
  evidence:
  - reference: PMID:34193815
    reference_title: Acute promyelocytic leukemia current treatment algorithms.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      It binds to retinoic acid response elements of target genes and recruits
      co-repressors such as DNA methyltransferases and histone deacetylases
    explanation: The review describes the corepressor and chromatin-repressor complex recruited by PML::RARA.
  downstream:
  - target: Repression of the Granulocytic Differentiation Program
    description: Corepressor recruitment suppresses transcription of genes needed for granulocytic differentiation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:34193815
      reference_title: Acute promyelocytic leukemia current treatment algorithms.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        which finally leads to suppression of genes necessary for granulocytic
        differentiation
      explanation: This is the stated transcriptional consequence of the recruited repressors.

- name: Repression of the Granulocytic Differentiation Program
  description: >-
    Repression of RARA-responsive and other myeloid genes prevents normal
    activation of the transcriptional program required for granulocyte
    maturation.
  cell_types:
  - preferred_term: promyelocyte
    term:
      id: CL:0000836
      label: promyelocyte
  biological_processes:
  - preferred_term: granulocyte differentiation
    modifier: DECREASED
    term:
      id: GO:0030851
      label: granulocyte differentiation
  evidence:
  - reference: PMID:16352814
    reference_title: ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Here we found that conditional expression of promyelocytic
      leukemia-retinoic acid receptor alpha (PML-RARA), the protein encoded by
      the t(15;17) translocation found in acute promyelocytic leukemia (APL),
      suppressed PU.1 expression
    explanation: Conditional PML-RARA expression suppresses a key myeloid-differentiation transcription factor.
  downstream:
  - target: Granulocytic Differentiation Arrest
    description: Failure to activate the granulocytic program arrests maturation near the promyelocyte stage.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:16352814
      reference_title: ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        treatment of APL cell lines and primary cells with all-trans retinoic
        acid (ATRA) restored PU.1 expression and induced neutrophil
        differentiation.
      explanation: Restoration of PU.1 reverses the differentiation block, supporting the causal link.

- name: Granulocytic Differentiation Arrest
  description: >-
    PML::RARA-expressing myeloid cells fail to complete neutrophil maturation,
    creating a preleukemic compartment from which overt APL can emerge.
  cell_types:
  - preferred_term: promyelocyte
    term:
      id: CL:0000836
      label: promyelocyte
  biological_processes:
  - preferred_term: neutrophil differentiation
    modifier: DECREASED
    term:
      id: GO:0030223
      label: neutrophil differentiation
  evidence:
  - reference: PMID:9122233
    reference_title: A PMLRARalpha transgene initiates murine acute promyelocytic leukemia.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      PMLRAR alpha transgenic mice exhibited impaired neutrophil maturation
      early in life, which progressed at a low frequency over the course of
      several months to overt APL.
    explanation: The transgenic model connects impaired maturation to a preleukemic state and later APL.
  downstream:
  - target: Promyelocyte Compartment Expansion
    description: Differentiation-arrested promyelocytes acquire increased proliferation and expand.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - altered cell-fate decisions and increased cell-cycle gene expression
    evidence:
    - reference: PMID:26088929
      reference_title: Transcription and methylation analyses of preleukemic promyelocytes indicate a dual role for PML/RARA in leukemia initiation.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Further, gene set enrichment analysis revealed that PML/RARA
        promyelocytes exhibit a subtle increase in expression of cell cycle
        genes, and we show that this leads to both increased proliferation of
        these cells and expansion of the promyelocyte compartment.
      explanation: The model identifies the proliferative intermediate linking the preleukemic state to compartment expansion.

- name: PML Nuclear-Body Disassembly
  description: >-
    PML::RARA disrupts the formation and signaling functions of PML nuclear
    bodies, compromising the tumor-suppressive programs coordinated by PML.
  cell_types:
  - preferred_term: promyelocyte
    term:
      id: CL:0000836
      label: promyelocyte
  cellular_components:
  - preferred_term: PML body
    term:
      id: GO:0016605
      label: PML body
  evidence:
  - reference: PMID:24344243
    reference_title: "Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Mechanistically, PML-RARa acts as a transcriptional repressor of RARa and
      non-RARa target genes and antagonizes the formation and function of PML
      nuclear bodies that regulate numerous signaling pathways.
    explanation: This directly supports PML nuclear-body disruption by the fusion oncoprotein.
  downstream:
  - target: Loss of PML-Mediated Senescence
    description: Nuclear-body dysfunction compromises PML-mediated senescence.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:38503502
      reference_title: "Acute Promyelocytic Leukemia, Retinoic Acid, and Arsenic: A Tale of Dualities."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        this simple (and sometimes sole) genetic alteration can transform
        hematopoietic progenitors through the acquisition of dominant-negative
        properties toward both transcriptional control by nuclear receptors and
        PML-mediated senescence
      explanation: The review identifies dominant-negative loss of PML-mediated senescence as a transformation mechanism.

- name: Loss of PML-Mediated Senescence
  description: >-
    Dominant-negative impairment of PML-mediated senescence permits persistence
    and transformation of fusion-expressing hematopoietic progenitors.
  cell_types:
  - preferred_term: promyelocyte
    term:
      id: CL:0000836
      label: promyelocyte
  biological_processes:
  - preferred_term: cellular senescence
    modifier: DECREASED
    term:
      id: GO:0090398
      label: cellular senescence
  evidence:
  - reference: PMID:38503502
    reference_title: "Acute Promyelocytic Leukemia, Retinoic Acid, and Arsenic: A Tale of Dualities."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      this simple (and sometimes sole) genetic alteration can transform
      hematopoietic progenitors through the acquisition of dominant-negative
      properties toward both transcriptional control by nuclear receptors and
      PML-mediated senescence
    explanation: This supports failure of PML-mediated senescence in fusion-driven transformation.
  downstream:
  - target: Promyelocyte Compartment Expansion
    description: Failure of senescence permits persistence and expansion of the abnormal clone.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - failure of oncogene-induced senescence and clonal persistence
    evidence:
    - reference: PMID:38503502
      reference_title: "Acute Promyelocytic Leukemia, Retinoic Acid, and Arsenic: A Tale of Dualities."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        this simple (and sometimes sole) genetic alteration can transform
        hematopoietic progenitors through the acquisition of dominant-negative
        properties toward both transcriptional control by nuclear receptors and
        PML-mediated senescence
      explanation: The source supports transformation through impaired senescence but does not directly quantify clonal expansion.

- name: FLT3-ITD-Driven Proliferative Signaling
  description: >-
    Activating FLT3 internal tandem duplication can provide a cooperating
    proliferative signal in PML::RARA-expressing hematopoietic cells. In the
    cited mouse model, the combination shortened leukemia latency and produced
    a fully penetrant APL-like disease; this node does not imply that FLT3-ITD
    is required in human APL.
  gene:
    preferred_term: FLT3
    term:
      id: hgnc:3765
      label: FLT3
  cell_types:
  - preferred_term: hematopoietic cell
    term:
      id: CL:0000988
      label: hematopoietic cell
  evidence:
  - reference: PMID:12060771
    reference_title: PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Activating mutations in FLT3, including internal tandem duplication (ITD)
      in the juxtamembrane domain, transform hematopoietic cell lines to factor
      independent growth.
    explanation: The model paper identifies the proliferative effect of activating FLT3-ITD.
  downstream:
  - target: Promyelocyte Compartment Expansion
    description: FLT3-ITD cooperates with PML::RARA to accelerate expansion into an APL-like disease.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - factor-independent growth and shortened leukemia latency
    evidence:
    - reference: PMID:12060771
      reference_title: PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Retroviral transduction of FLT3-ITD into bone marrow cells obtained from
        PML/RARalpha transgenic mice results in a short latency APL-like disease
        with complete penetrance.
      explanation: The combination accelerates and fully penetrates the APL-like phenotype in this mouse model.

- name: Promyelocyte Compartment Expansion
  description: >-
    Morphologically abnormal, granule-rich promyelocytes expand in bone marrow
    and can appear in peripheral blood.
  locations:
  - preferred_term: bone marrow
    term:
      id: UBERON:0002371
      label: bone marrow
  cell_types:
  - preferred_term: promyelocyte
    term:
      id: CL:0000836
      label: promyelocyte
  evidence:
  - reference: PMID:397771
    reference_title: "Acute promyelocytic leukemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Acute promyelocytic leukemia (APL) is characterized by proliferation of
      morphologically abnormal promyelocytes and a severe bleeding diathesis.
      The abnormal promyelocyte is characterized by abundant, large granules,
      many of which are spindle-shaped.
    explanation: The overview describes the defining expansion and morphology of APL promyelocytes.
  downstream:
  - target: Promyelocyte Procoagulant Activity
    description: Granule-associated tissue thromboplastin activity links abnormal promyelocytes to coagulation activation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:397771
      reference_title: "Acute promyelocytic leukemia."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        The granules appear to possess tissue thromboplastin activity by both
        immunologic and clotting assays.
      explanation: The source directly identifies procoagulant activity in APL promyelocyte granules.
  - target: Bone marrow hypercellularity
    description: Expansion of abnormal promyelocytes is associated with a hypercellular marrow.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:520
      reference_title: Acute promyelocytic leukemia
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0031020 | Bone marrow hypercellularity | Frequent (79-30%)"
      explanation: Orphanet supports the association and frequency, but not the full causal direction.
  - target: Suppression of Normal Hematopoiesis
    description: Marrow expansion of abnormal promyelocytes is inferred to suppress production of normal blood-cell lineages.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:520
      reference_title: Acute promyelocytic leukemia
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001876 | Pancytopenia | Frequent (79-30%)"
      explanation: Orphanet supports the associated multilineage cytopenia, but not the inferred marrow-suppression mechanism.

- name: Suppression of Normal Hematopoiesis
  description: >-
    Expansion of the leukemic promyelocyte compartment is inferred to impair
    normal marrow output, providing a common intermediate for multilineage
    cytopenias. Available evidence here establishes the clinical associations,
    so these links remain partial rather than asserted as directly proven.
  locations:
  - preferred_term: bone marrow
    term:
      id: UBERON:0002371
      label: bone marrow
  evidence:
  - reference: ORPHA:520
    reference_title: Acute promyelocytic leukemia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001876 | Pancytopenia | Frequent (79-30%)"
    explanation: Frequent pancytopenia supports impaired multilineage marrow output as a plausible intermediate.
  downstream:
  - target: Pancytopenia
    description: Impaired normal marrow output manifests as reduction across multiple blood-cell lineages.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:520
      reference_title: Acute promyelocytic leukemia
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001876 | Pancytopenia | Frequent (79-30%)"
      explanation: Orphanet supports the clinical association but does not directly test this mechanistic direction.
  - target: Anemia
    description: Impaired erythroid output is a plausible contributor to anemia in APL.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:520
      reference_title: Acute promyelocytic leukemia
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001903 | Anemia | Frequent (79-30%)"
      explanation: Orphanet supports the clinical association but does not directly test this mechanistic direction.
  - target: Thrombocytopenia
    description: Impaired megakaryopoiesis can contribute to thrombocytopenia alongside consumptive coagulopathy.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:520
      reference_title: Acute promyelocytic leukemia
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001873 | Thrombocytopenia | Frequent (79-30%)"
      explanation: Orphanet supports the clinical association but does not isolate marrow suppression from consumption.
  - target: Leukopenia
    description: Impaired production of normal leukocyte lineages is a plausible contributor to leukopenia.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:520
      reference_title: Acute promyelocytic leukemia
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001882 | Leukopenia | Frequent (79-30%)"
      explanation: Orphanet supports the clinical association but does not directly test this mechanistic direction.

- name: Promyelocyte Procoagulant Activity
  description: >-
    Abnormal promyelocyte granules exhibit tissue thromboplastin activity,
    providing a direct route to systemic coagulation activation.
  cell_types:
  - preferred_term: promyelocyte
    term:
      id: CL:0000836
      label: promyelocyte
  biological_processes:
  - preferred_term: blood coagulation
    modifier: INCREASED
    term:
      id: GO:0007596
      label: blood coagulation
  evidence:
  - reference: PMID:397771
    reference_title: "Acute promyelocytic leukemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The granules appear to possess tissue thromboplastin activity by both
      immunologic and clotting assays.
    explanation: This is direct biochemical evidence of promyelocyte-associated procoagulant activity.
  downstream:
  - target: Systemic Coagulation Activation and Consumptive Coagulopathy
    description: Promyelocyte-associated thromboplastin activity plausibly contributes to systemic coagulation activation and consumption.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - tissue-factor pathway activation and consumption of platelets and coagulation factors
    evidence:
    - reference: PMID:397771
      reference_title: "Acute promyelocytic leukemia."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        The granules appear to possess tissue thromboplastin activity by both
        immunologic and clotting assays. Coagulation studies in APL are
        generally consistent with disseminated intravascular coagulation.
      explanation: The source juxtaposes promyelocyte thromboplastin activity with the DIC pattern but does not directly test the full causal chain.

- name: Systemic Coagulation Activation and Consumptive Coagulopathy
  description: >-
    APL produces a complex coagulopathy with clinically important hemorrhagic
    and thrombotic events. Consumptive coagulation is established, while modern
    reviews emphasize that the full hemostatic disturbance is broader than a
    single DIC mechanism.
  biological_processes:
  - preferred_term: blood coagulation
    modifier: ABNORMAL
    term:
      id: GO:0007596
      label: blood coagulation
  evidence:
  - reference: PMID:397771
    reference_title: "Acute promyelocytic leukemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Coagulation studies in APL are generally consistent with disseminated
      intravascular coagulation.
    explanation: The source establishes the consumptive DIC pattern in APL.
  - reference: PMID:37444587
    reference_title: "The Coagulopathy of Acute Promyelocytic Leukemia: An Updated Review of Pathophysiology, Risk Stratification, and Clinical Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      However, there remains a considerable morbidity and mortality risk in APL
      secondary to clinically significant hemorrhagic and/or thrombotic events.
    explanation: The updated review documents both hemorrhagic and thrombotic clinical consequences.
  downstream:
  - target: Disseminated Intravascular Coagulation
    description: Systemic coagulation activation manifests as disseminated intravascular coagulation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:397771
      reference_title: "Acute promyelocytic leukemia."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Coagulation studies in APL are generally consistent with disseminated
        intravascular coagulation.
      explanation: The source directly identifies the DIC manifestation.
  - target: Abnormal Bleeding
    description: Coagulation-factor and platelet consumption contribute to the severe bleeding diathesis.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - consumption of platelets and coagulation factors
    evidence:
    - reference: PMID:397771
      reference_title: "Acute promyelocytic leukemia."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Acute promyelocytic leukemia (APL) is characterized by proliferation of
        morphologically abnormal promyelocytes and a severe bleeding diathesis.
      explanation: The source establishes severe bleeding, while the specific intermediate consumption mechanism is inferred.

- name: Differentiation Therapy-Induced Promyelocyte Maturation
  description: >-
    During induction, ATRA and/or ATO drive rapid differentiation of leukemic
    blasts and promyelocytes. This therapeutic response can also initiate the
    cellular migration and endothelial signaling that precede differentiation
    syndrome.
  cell_types:
  - preferred_term: promyelocyte
    term:
      id: CL:0000836
      label: promyelocyte
  biological_processes:
  - preferred_term: neutrophil differentiation
    modifier: INCREASED
    term:
      id: GO:0030223
      label: neutrophil differentiation
  evidence:
  - reference: PMID:22220256
    reference_title: "The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The differentiation of leukemic blasts and promyelocytes induced by ATRA
      and/or ATO may lead to cellular migration, endothelial activation, and
      release of interleukins and vascular factors responsible of tissue damage.
    explanation: The review connects therapy-induced differentiation to the initiating events of differentiation syndrome.
  downstream:
  - target: Differentiation Syndrome Inflammatory-Endothelial Response
    description: Differentiating cells migrate and activate endothelial and inflammatory signaling.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:22220256
      reference_title: "The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        The differentiation of leukemic blasts and promyelocytes induced by ATRA
        and/or ATO may lead to cellular migration, endothelial activation, and
        release of interleukins and vascular factors responsible of tissue damage.
      explanation: The source specifies the cellular and endothelial events downstream of induced differentiation.

- name: Differentiation Syndrome Inflammatory-Endothelial Response
  description: >-
    Cellular migration, endothelial activation, interleukin and vascular-factor
    release, tissue infiltration, and capillary leak contribute to
    differentiation syndrome. The relative contribution of these mechanisms
    remains incompletely resolved.
  biological_processes:
  - preferred_term: cytokine-mediated signaling pathway
    modifier: INCREASED
    term:
      id: GO:0019221
      label: cytokine-mediated signaling pathway
  - preferred_term: leukocyte migration
    modifier: INCREASED
    term:
      id: GO:0050900
      label: leukocyte migration
  evidence:
  - reference: PMID:22220256
    reference_title: "The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The differentiation of leukemic blasts and promyelocytes induced by ATRA
      and/or ATO may lead to cellular migration, endothelial activation, and
      release of interleukins and vascular factors responsible of tissue damage.
    explanation: The review supports a multi-component inflammatory and endothelial response rather than a cytokine-only model.
  downstream:
  - target: Differentiation Syndrome
    description: The inflammatory-endothelial response produces the clinical differentiation syndrome.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - tissue infiltration and vascular capillary leak
    evidence:
    - reference: PMID:22220256
      reference_title: "The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Roughly one quarter of patients with APL undergoing induction therapy
        will develop the DS, characterized by unexplained fever, acute
        respiratory distress with interstitial pulmonary infiltrates, and/or a
        vascular capillary leak syndrome leading to acute renal failure.
      explanation: The review links the induction setting and capillary-leak response to the clinical syndrome.

histopathology:
- name: Abnormal Granule-Rich Promyelocytes
  description: >-
    Marrow and blood contain morphologically abnormal promyelocytes with
    abundant large granules, including spindle-shaped granules.
  diagnostic: true
  evidence:
  - reference: PMID:397771
    reference_title: "Acute promyelocytic leukemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Acute promyelocytic leukemia (APL) is characterized by proliferation of
      morphologically abnormal promyelocytes and a severe bleeding diathesis.
      The abnormal promyelocyte is characterized by abundant, large granules,
      many of which are spindle-shaped.
    explanation: The complete snippet identifies both abnormal promyelocytes and their characteristic granules.
- name: Characteristic Flow-Cytometric Immunophenotype
  description: >-
    Classical APL commonly shows CD13, CD33, CD117, and HLA-DR
    negativity; variant patterns occur, so immunophenotyping supports rapid
    suspicion but does not replace molecular confirmation.
  evidence:
  - reference: PMID:22535601
    reference_title: "Acute promyelocytic leukemia: four distinct patterns by flow cytometry immunophenotyping."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Leukemic cells had the following phenotype: CD11b-, CD11c-, CD13+, CD33+,
      CD45+, CD64+/-, CD117+, and HLA-DR-.
    explanation: The 97-patient series defines the characteristic core immunophenotype while also documenting variants.

phenotypes:
- category: Hematologic
  name: Pancytopenia
  frequency: FREQUENT
  description: Reduction across erythroid, myeloid, and platelet lineages.
  phenotype_term:
    preferred_term: Pancytopenia
    term:
      id: HP:0001876
      label: Pancytopenia
  evidence:
  - reference: ORPHA:520
    reference_title: Acute promyelocytic leukemia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001876 | Pancytopenia | Frequent (79-30%)"
    explanation: Orphanet classifies pancytopenia as frequent.
- category: Hematologic
  name: Disseminated Intravascular Coagulation
  frequency: FREQUENT
  diagnostic: true
  description: A consumptive coagulopathy that contributes to the hemorrhagic emergency of APL.
  phenotype_term:
    preferred_term: Disseminated intravascular coagulation
    term:
      id: HP:0005521
      label: Disseminated intravascular coagulation
  evidence:
  - reference: ORPHA:520
    reference_title: Acute promyelocytic leukemia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0005521 | Disseminated intravascular coagulation | Frequent (79-30%)"
    explanation: Orphanet classifies DIC as frequent.
- category: Bleeding
  name: Abnormal Bleeding
  frequency: FREQUENT
  description: Bleeding may range from mucocutaneous hemorrhage to severe organ bleeding.
  phenotype_term:
    preferred_term: Abnormal bleeding
    term:
      id: HP:0001892
      label: Abnormal bleeding
  evidence:
  - reference: ORPHA:520
    reference_title: Acute promyelocytic leukemia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001892 | Abnormal bleeding | Frequent (79-30%)"
    explanation: Orphanet classifies abnormal bleeding as frequent.
- category: Hematologic
  name: Anemia
  frequency: FREQUENT
  description: Reduced red-cell mass in APL.
  phenotype_term:
    preferred_term: Anemia
    term:
      id: HP:0001903
      label: Anemia
  evidence:
  - reference: ORPHA:520
    reference_title: Acute promyelocytic leukemia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001903 | Anemia | Frequent (79-30%)"
    explanation: Orphanet classifies anemia as frequent.
- category: Hematologic
  name: Thrombocytopenia
  frequency: FREQUENT
  description: Reduced platelet count in APL.
  phenotype_term:
    preferred_term: Thrombocytopenia
    term:
      id: HP:0001873
      label: Thrombocytopenia
  evidence:
  - reference: ORPHA:520
    reference_title: Acute promyelocytic leukemia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001873 | Thrombocytopenia | Frequent (79-30%)"
    explanation: Orphanet classifies thrombocytopenia as frequent.
- category: Hematologic
  name: Leukopenia
  frequency: FREQUENT
  description: Reduced total leukocyte count can occur despite abnormal promyelocyte expansion.
  phenotype_term:
    preferred_term: Leukopenia
    term:
      id: HP:0001882
      label: Decreased total leukocyte count
  evidence:
  - reference: ORPHA:520
    reference_title: Acute promyelocytic leukemia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001882 | Leukopenia | Frequent (79-30%)"
    explanation: Orphanet classifies leukopenia as frequent.
- category: Constitutional
  name: Fever
  frequency: FREQUENT
  description: Fever may accompany presentation.
  phenotype_term:
    preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
  evidence:
  - reference: ORPHA:520
    reference_title: Acute promyelocytic leukemia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001945 | Fever | Frequent (79-30%)"
    explanation: Orphanet classifies fever as frequent.
- category: Hematologic
  name: Bone marrow hypercellularity
  frequency: FREQUENT
  description: Hypercellular marrow associated with leukemic promyelocyte expansion.
  phenotype_term:
    preferred_term: Bone marrow hypercellularity
    term:
      id: HP:0031020
      label: Bone marrow hypercellularity
  evidence:
  - reference: ORPHA:520
    reference_title: Acute promyelocytic leukemia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0031020 | Bone marrow hypercellularity | Frequent (79-30%)"
    explanation: Orphanet classifies bone marrow hypercellularity as frequent.
- category: Constitutional
  name: Fatigue
  frequency: FREQUENT
  description: Fatigue accompanies the systemic effects and cytopenias of APL.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
  evidence:
  - reference: ORPHA:520
    reference_title: Acute promyelocytic leukemia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0012378 | Fatigue | Frequent (79-30%)"
    explanation: Orphanet classifies fatigue as frequent.
- category: Treatment complication
  name: Differentiation Syndrome
  description: >-
    During ATRA and/or ATO induction, unexplained fever, weight gain, dyspnea,
    pulmonary infiltrates or effusions, hypotension, and renal failure can occur
    as a potentially severe treatment complication.
  context: During induction with differentiating agents
  evidence:
  - reference: PMID:24627526
    reference_title: How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The full-blown syndrome consists of unexplained fever, weight gain, dyspnea
      with pulmonary infiltrates, pleuropericardial effusion, hypotension, and
      renal failure.
    explanation: The review defines the clinical syndrome without assigning a universal frequency.

biochemical:
- name: Consumptive Coagulation Profile
  notes: >-
    APL coagulopathy commonly includes prolonged PT and PTT, elevated D-dimer,
    hypofibrinogenemia, and thrombocytopenia; individual results and treatment
    thresholds require clinical interpretation.
  evidence:
  - reference: PMID:34193815
    reference_title: Acute promyelocytic leukemia current treatment algorithms.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      A consumptive coagulopathy consisting of elevated partial thromboplastin
      time (PTT), prothrombin time (PT), and D-dimers, together with
      hypofibrinogenemia, and thrombocytopenia is another common feature present
      in three-quarters of the patients at diagnosis [15].
    explanation: The review supports the listed coagulation abnormalities and their common occurrence at diagnosis.
  readouts:
  - target: Systemic Coagulation Activation and Consumptive Coagulopathy
    relationship: READOUT_OF
    direction: THRESHOLD_DEPENDENT
    endpoint_context: MONITORING
    interpretation: The combined coagulation profile reflects the severity and evolution of APL coagulopathy.
    evidence:
    - reference: PMID:34193815
      reference_title: Acute promyelocytic leukemia current treatment algorithms.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        A consumptive coagulopathy consisting of elevated partial thromboplastin
        time (PTT), prothrombin time (PT), and D-dimers, together with
        hypofibrinogenemia, and thrombocytopenia is another common feature present
        in three-quarters of the patients at diagnosis [15].
      explanation: The measured profile is a readout of the consumptive coagulopathy node.
- name: PML-RARA Fusion Transcript
  notes: >-
    Detection establishes the molecular identity of this APL entry. Quantitative
    PCR is also used at protocol-defined response milestones and during
    follow-up; molecular complete remission at the end of consolidation is the
    response milestone represented here.
  evidence:
  - reference: DOI:10.3390/cancers16061160
    reference_title: "Acute Promyelocytic Leukemia: Review of Complications Related to All-Trans Retinoic Acid and Arsenic Trioxide Therapy"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The hallmark of acute promyelocytic leukemia (APL) is the presence of the
      characteristic fusion transcript of the promyelocytic leukemia gene with
      the retinoic acid receptor α gene (PML::RARA).
    explanation: The review identifies the fusion transcript as the molecular hallmark.
  readouts:
  - target: Somatic PML-RARA Fusion
    relationship: READOUT_OF
    direction: PRESENT_ABSENT
    endpoint_context: DIAGNOSTIC
    interpretation: Detection of the fusion transcript confirms the molecular lesion represented by the root node.
    evidence:
    - reference: DOI:10.3390/cancers16061160
      reference_title: "Acute Promyelocytic Leukemia: Review of Complications Related to All-Trans Retinoic Acid and Arsenic Trioxide Therapy"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        The hallmark of acute promyelocytic leukemia (APL) is the presence of the
        characteristic fusion transcript of the promyelocytic leukemia gene with
        the retinoic acid receptor α gene (PML::RARA).
      explanation: Presence of the transcript directly reports the fusion lesion.
  - target: Promyelocyte Compartment Expansion
    relationship: CORRELATES_WITH
    direction: POSITIVE
    endpoint_context: MONITORING
    interpretation: End-of-consolidation molecular response and subsequent PML::RARA PCR monitoring report residual or recurrent leukemic burden.
    evidence:
    - reference: DOI:10.3390/cancers16183208
      reference_title: "MRD in Acute Leukemias: Lessons Learned from Acute Promyelocytic Leukemia"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Acute promyelocytic leukemia (APL) leads the way in this transformation,
        initially using PCR to detect MRD in patients in remission, and more
        recently, aiming to eliminate it entirely with modern treatment strategies.
      explanation: The review supports PCR-based monitoring of residual disease in APL remission.
    - reference: PMID:34193815
      reference_title: Acute promyelocytic leukemia current treatment algorithms.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Maintenance therapy is not part of our standard practice for patients
        who achieve molecular CR at the end of consolidation with ATRA plus ATO
        based regimens.
      explanation: The treatment review identifies molecular complete remission at the end of consolidation as a defined response milestone.

genetic:
- name: PML Fusion Partner
  gene_term:
    preferred_term: PML
    term:
      id: hgnc:9113
      label: PML
  association: 5-prime partner in the defining somatic PML::RARA fusion driver
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  notes: >-
    PML is one partner in the defining somatic PML::RARA rearrangement, usually
    the classic t(15;17) but sometimes a cryptic or complex insertion. The
    fusion is not described here as sufficient by itself for full leukemic
    transformation because model systems show latency, incomplete penetrance,
    and cooperation with additional lesions.
  evidence:
  - reference: PMID:39858554
    reference_title: "Utilization of RT-PCR and Optical Genome Mapping in Acute Promyelocytic Leukemia with Cryptic PML::RARA Rearrangement: A Case Discussion and Systemic Literature Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Acute promyelocytic leukemia (APL) is characterized by abnormal
      promyelocytes and t(15;17)(q24;q21) PML::RARA.
    explanation: The clinical review identifies PML as a partner in the defining fusion.
  - reference: PMID:9122233
    reference_title: A PMLRARalpha transgene initiates murine acute promyelocytic leukemia.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Our results demonstrate that PMLRAR alpha impairs neutrophil
      differentiation and initiates the development of APL.
    explanation: The transgenic model supports an initiating-driver relationship.
  - reference: PMID:12060771
    reference_title: PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Expression of PML/RARalpha from the cathepsin G promoter in transgenic mice
      causes a nonfatal myeloproliferative syndrome in all mice; about 15% go on
      to develop APL after a long latent period, suggesting that additional
      mutations are required for the development of APL.
    explanation: The model directly supports long latency, incomplete penetrance, and the need for cooperating events.
- name: RARA Fusion Partner
  gene_term:
    preferred_term: RARA
    term:
      id: hgnc:9864
      label: RARA
  association: 3-prime partner in the defining somatic PML::RARA fusion driver
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  notes: >-
    RARA is the retinoic-acid receptor partner in the defining PML::RARA
    rearrangement, most often t(15;17). The resulting fusion protein recruits
    corepressors and disrupts the normal granulocytic differentiation program.
  evidence:
  - reference: PMID:39858554
    reference_title: "Utilization of RT-PCR and Optical Genome Mapping in Acute Promyelocytic Leukemia with Cryptic PML::RARA Rearrangement: A Case Discussion and Systemic Literature Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Acute promyelocytic leukemia (APL) is characterized by abnormal
      promyelocytes and t(15;17)(q24;q21) PML::RARA.
    explanation: The clinical review identifies RARA as a partner in the defining fusion.
- name: FLT3
  gene_term:
    preferred_term: FLT3
    term:
      id: hgnc:3765
      label: FLT3
  association: Cooperating somatic alteration and prognostic biomarker
  relationship_type: COOPERATING
  variant_origin: SOMATIC
  notes: >-
    FLT3-ITD can cooperate with PML::RARA in experimental leukemogenesis and has
    been associated with adverse progression-free survival in a human
    ATRA-plus-chemotherapy cohort. No universal case frequency or
    treatment-intensification rule is asserted.
  evidence:
  - reference: PMID:12060771
    reference_title: PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      These observations document cooperation between PML/RARalpha and FLT3-ITD
      in development of the murine APL phenotype.
    explanation: The model directly demonstrates functional cooperation.
  - reference: PMID:36539954
    reference_title: Association between FLT3-ITD and additional chromosomal abnormalities in the prognosis of acute promyelocytic leukemia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      FLT3-ITD was an independent adverse factor for 5-year PFS, and ACA was an
      independent adverse factor for 5-year OS.
    explanation: The human cohort supports a prognostic association without establishing a treatment rule.

diagnosis:
- name: Morphologic Suspicion of APL
  description: >-
    Peripheral blood and marrow morphology showing abnormal promyelocytes with
    irregular azurophilic granules or Auer rods should trigger urgent evaluation
    and empiric ATRA while molecular confirmation is pursued.
  evidence:
  - reference: PMID:34193815
    reference_title: Acute promyelocytic leukemia current treatment algorithms.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Microscopic identification of circulating promyelocytes with irregular
      azurophilic granules or Auer rods strongly supports APL diagnosis.
    explanation: The review identifies the morphology that strongly supports rapid suspicion.
  - reference: PMID:34193815
    reference_title: Acute promyelocytic leukemia current treatment algorithms.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Immediate administration of ATRA at the first suspicion of APL diagnosis
      is of extreme importance.
    explanation: The review directly supports empiric ATRA at morphologic suspicion while confirmation is pursued.
- name: Molecular Confirmation of PML::RARA
  description: >-
    Confirm the PML::RARA fusion by molecular testing. A negative conventional
    karyotype does not exclude cryptic or complex rearrangements, so RT-PCR or
    another sensitive molecular method is important when morphology remains
    compelling.
  results: PML::RARA fusion transcript detected
  evidence:
  - reference: PMID:34193815
    reference_title: Acute promyelocytic leukemia current treatment algorithms.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In the majority of such cases, a molecular analysis nevertheless reveals
      an underlying PML–RARA fusion transcript formed as a result of
      cytogenetically cryptic or complex insertion events [2].
    explanation: The review supports molecular detection when classic cytogenetic findings are absent.
  - reference: PMID:39858554
    reference_title: "Utilization of RT-PCR and Optical Genome Mapping in Acute Promyelocytic Leukemia with Cryptic PML::RARA Rearrangement: A Case Discussion and Systemic Literature Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "RT-PCR revealed a cryptic PML::RARA fusion transcript."
    explanation: A cryptic clinical case demonstrates the value of RT-PCR confirmation.
- name: Supportive Flow-Cytometric Immunophenotyping
  description: >-
    Flow cytometry can rapidly identify a characteristic APL pattern and
    prioritize confirmatory fusion testing, but variant immunophenotypes prevent
    it from being a stand-alone molecular diagnosis.
  markers: CD13+, CD33+, CD117+, HLA-DR- with variant patterns
  evidence:
  - reference: PMID:22535601
    reference_title: "Acute promyelocytic leukemia: four distinct patterns by flow cytometry immunophenotyping."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Apart from a well-known FC pattern of hypergranular APL, we presented less
      common immunophenotypic variants of APL, which helps to identify an
      additional group of patients who would benefit from fast confirmatory FISH
      and/or PCR testing for t(15;17)/PML-RARA.
    explanation: The study supports flow cytometry as a triage tool for rapid confirmatory testing.

differential_diagnoses:
- name: APL-Like Acute Myeloid Leukemia Without PML::RARA
  description: >-
    A small, genetically heterogeneous group of AMLs can show APL-like
    morphology or immunophenotype without t(15;17). Molecular confirmation is
    decisive because these entities differ in genetics, therapy sensitivity,
    and prognosis.
  distinguishing_features:
  - Absence of the defining PML::RARA fusion
  - Alternative genetic lesion on expanded molecular testing
  - Therapy response may differ from PML::RARA-positive APL
  evidence:
  - reference: DOI:10.3390/cancers16244192
    reference_title: "Acute Promyelocytic Leukemia-like AML: Genetic Perspective and Clinical Implications"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      However, a small percentage (estimated to be 2%) of AML presenting with
      APL-like morphology and/or immunophenotype lacks t(15;17).
    explanation: The review directly identifies the molecularly distinct APL-like differential group.

animal_models:
- species: Mus musculus
  genotype: Myeloid-cell PMLRARalpha transgenic mouse
  genes:
  - preferred_term: PML
    term:
      id: hgnc:9113
      label: PML
  - preferred_term: RARA
    term:
      id: hgnc:9864
      label: RARA
  description: >-
    Myeloid expression of PMLRARalpha produces early impaired neutrophil
    maturation, a transplantable preleukemic state, and low-frequency,
    long-latency APL that remains retinoic-acid responsive. The model separates
    fusion-driven initiation from the additional events required for efficient
    progression.
  associated_phenotypes:
  - Impaired neutrophil maturation
  - Preleukemic promyelocyte expansion
  - Retinoic-acid-responsive APL
  evidence:
  - reference: PMID:9122233
    reference_title: A PMLRARalpha transgene initiates murine acute promyelocytic leukemia.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      PMLRAR alpha transgenic mice exhibited impaired neutrophil maturation
      early in life, which progressed at a low frequency over the course of
      several months to overt APL.
    explanation: The model reproduces the maturation defect and low-frequency progression to overt leukemia.
  - reference: PMID:9122233
    reference_title: A PMLRARalpha transgene initiates murine acute promyelocytic leukemia.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Both the preleukemic state and the leukemia could be transplanted to
      nontransgenic mice, and the transplanted preleukemia could progress to APL.
    explanation: The experiment directly supports transplantability of both the preleukemic and leukemic states.
  - reference: PMID:9122233
    reference_title: A PMLRARalpha transgene initiates murine acute promyelocytic leukemia.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The APL recapitulated features of the human disease, including a response
      to retinoic acid. Retinoic acid caused the leukemic cells to differentiate
      in vitro and in vivo, eliciting remissions of both the preleukemic state
      and APL in mice.
    explanation: The model directly supports retinoic-acid responsiveness and remission.
- species: Mus musculus
  genotype: PML/RARalpha transgenic marrow with retroviral FLT3-ITD
  genes:
  - preferred_term: PML
    term:
      id: hgnc:9113
      label: PML
  - preferred_term: RARA
    term:
      id: hgnc:9864
      label: RARA
  - preferred_term: FLT3
    term:
      id: hgnc:3765
      label: FLT3
  description: >-
    FLT3-ITD transduction of marrow from PML/RARalpha transgenic mice yields a
    short-latency, fully penetrant, transplantable, ATRA-responsive APL-like
    disease, directly testing genetic cooperation.
  associated_phenotypes:
  - Short-latency APL-like leukemia
  - Transplantable leukemia
  - ATRA responsiveness
  evidence:
  - reference: PMID:12060771
    reference_title: PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Retroviral transduction of FLT3-ITD into bone marrow cells obtained from
      PML/RARalpha transgenic mice results in a short latency APL-like disease
      with complete penetrance.
    explanation: The experiment directly demonstrates rapid, penetrant disease after combining the two lesions.
  - reference: PMID:12060771
    reference_title: PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The leukemia is transplantable to secondary recipients and is ATRA responsive."
    explanation: The experiment directly supports the two additional model properties stated in the description.

progression:
- phase: Early hemorrhagic-risk presentation
  notes: >-
    Newly suspected APL is an urgent condition requiring prompt recognition to
    avoid early mortality; a severe bleeding diathesis can already be present at
    presentation.
  evidence:
  - reference: PMID:38890097
    reference_title: "Diagnosis and management of acute promyelocytic leukemia: Brazilian consensus guidelines 2024 on behalf of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Finally, acute promyelocytic leukemia is presented as a highly curable
      disease because of the real possibility of targeted therapy towards
      differentiation, and, paradoxically, as a serious and urgent condition
      that deserves prompt recognition and management to avoid early mortality.
    explanation: The current consensus identifies the urgent early-mortality phase.
  - reference: PMID:397771
    reference_title: "Acute promyelocytic leukemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Acute promyelocytic leukemia (APL) is characterized by proliferation of
      morphologically abnormal promyelocytes and a severe bleeding diathesis.
    explanation: The review directly supports the severe bleeding risk present with APL.
- phase: Induction and differentiation-syndrome window
  notes: >-
    Differentiation syndrome occurs during induction with ATRA and/or ATO and
    requires prompt recognition; the mechanism includes differentiating-cell
    migration, endothelial activation, and vascular leak.
  evidence:
  - reference: PMID:22220256
    reference_title: "The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Roughly one quarter of patients with APL undergoing induction therapy will
      develop the DS, characterized by unexplained fever, acute respiratory
      distress with interstitial pulmonary infiltrates, and/or a vascular
      capillary leak syndrome leading to acute renal failure.
    explanation: The review places differentiation syndrome in the induction phase.
- phase: End-of-consolidation molecular response and follow-up
  notes: >-
    Molecular complete remission at the end of consolidation is the key response
    milestone represented here. Thereafter, PML::RARA PCR can detect residual or
    recurrent molecular disease during risk-adapted follow-up.
  evidence:
  - reference: PMID:34193815
    reference_title: Acute promyelocytic leukemia current treatment algorithms.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Maintenance therapy is not part of our standard practice for patients who
      achieve molecular CR at the end of consolidation with ATRA plus ATO based
      regimens.
    explanation: The treatment review identifies end-of-consolidation molecular complete remission as a response milestone.
  - reference: DOI:10.3390/cancers16183208
    reference_title: "MRD in Acute Leukemias: Lessons Learned from Acute Promyelocytic Leukemia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Acute promyelocytic leukemia (APL) leads the way in this transformation,
      initially using PCR to detect MRD in patients in remission, and more
      recently, aiming to eliminate it entirely with modern treatment strategies.
    explanation: The review supports PCR-based monitoring after the defined molecular-response milestone.

treatments:
- name: Immediate All-Trans Retinoic Acid (ATRA)
  description: >-
    ATRA should begin at the first clinical suspicion of APL while confirmatory
    testing proceeds. It releases PML::RARA-associated corepressors and restores
    terminal myeloid differentiation.
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: PML-RARA Corepressor Recruitment
    treatment_effect: INHIBITS
    description: Ligand binding releases corepressors and relieves fusion-mediated transcriptional repression.
    evidence:
    - reference: PMID:34193815
      reference_title: Acute promyelocytic leukemia current treatment algorithms.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        ATRA causes a conformational change of the PML–RARA fusion transcripts,
        leading to the release of the co-repressors, recruitment of histone
        acetyltransferases, and relief of transcriptional repression
      explanation: The review directly supports the ATRA target mechanism.
  - target: Differentiation Therapy-Induced Promyelocyte Maturation
    treatment_effect: ACTIVATES
    description: ATRA induces differentiation of leukemic blasts and promyelocytes.
    evidence:
    - reference: PMID:22220256
      reference_title: "The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        The differentiation of leukemic blasts and promyelocytes induced by ATRA
        and/or ATO may lead to cellular migration, endothelial activation, and
        release of interleukins and vascular factors responsible of tissue damage.
      explanation: The review directly identifies ATRA-induced promyelocyte differentiation.
  evidence:
  - reference: PMID:34193815
    reference_title: Acute promyelocytic leukemia current treatment algorithms.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Immediate administration of ATRA at the first suspicion of APL diagnosis
      is of extreme importance.
    explanation: The review supports immediate empiric initiation without asserting an unsupported universal dose.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: all-trans-retinoic acid
      term:
        id: CHEBI:15367
        label: all-trans-retinoic acid

- name: Arsenic Trioxide (ATO)
  description: >-
    ATO targets PML/PML::RARA, promotes fusion-protein degradation, and restores
    PML nuclear-body architecture.
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: PML Nuclear-Body Disassembly
    treatment_effect: INHIBITS
    description: ATO drives PML::RARA degradation and PML nuclear-body reformation.
    evidence:
    - reference: PMID:37655965
      reference_title: Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Arsenic trioxide (ATO) cures 70% of patients with APL, driving PML-RARA
        degradation and NB reformation.
      explanation: The mechanistic study directly supports degradation and nuclear-body reformation.
  - target: Differentiation Therapy-Induced Promyelocyte Maturation
    treatment_effect: ACTIVATES
    description: ATO induces differentiation of leukemic blasts and promyelocytes.
    evidence:
    - reference: PMID:22220256
      reference_title: "The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        The differentiation of leukemic blasts and promyelocytes induced by ATRA
        and/or ATO may lead to cellular migration, endothelial activation, and
        release of interleukins and vascular factors responsible of tissue damage.
      explanation: The review directly identifies ATO-induced promyelocyte differentiation.
  evidence:
  - reference: PMID:37655965
    reference_title: Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Arsenic curative effects in APL rely on PML targeting."
    explanation: The study identifies PML targeting as central to ATO efficacy.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: arsenic trioxide
      term:
        id: CHEBI:30621
        label: diarsenic trioxide

- name: ATRA plus ATO for Non-High-Risk APL
  description: >-
    For newly diagnosed non-high-risk APL (presenting white-cell count at or
    below 10 × 10^9/L), ATRA plus ATO is a chemotherapy-free induction and
    consolidation strategy supported by randomized phase III evidence.
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  regimen_term:
    preferred_term: Arsenic Trioxide/Tretinoin Regimen
    term:
      id: NCIT:C198431
      label: Arsenic Trioxide/Tretinoin Regimen
  target_mechanisms:
  - target: PML-RARA Corepressor Recruitment
    treatment_effect: INHIBITS
    description: The ATRA component relieves PML::RARA-mediated transcriptional repression.
    evidence:
    - reference: PMID:34193815
      reference_title: Acute promyelocytic leukemia current treatment algorithms.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        ATRA causes a conformational change of the PML–RARA fusion transcripts,
        leading to the release of the co-repressors, recruitment of histone
        acetyltransferases, and relief of transcriptional repression
      explanation: This supports the ATRA component's target mechanism.
  - target: PML Nuclear-Body Disassembly
    treatment_effect: INHIBITS
    description: The ATO component promotes PML::RARA degradation and nuclear-body reformation.
    evidence:
    - reference: PMID:37655965
      reference_title: Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Arsenic trioxide (ATO) cures 70% of patients with APL, driving PML-RARA
        degradation and NB reformation.
      explanation: This supports the ATO component's target mechanism.
  evidence:
  - reference: PMID:23841729
    reference_title: Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CONCLUSIONS: ATRA plus arsenic trioxide is at least not inferior and may
      be superior to ATRA plus chemotherapy in the treatment of patients with
      low-to-intermediate-risk APL.
    explanation: The randomized phase III trial supports the regimen specifically in low-to-intermediate-risk APL.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: all-trans-retinoic acid
      term:
        id: CHEBI:15367
        label: all-trans-retinoic acid
    - preferred_term: arsenic trioxide
      term:
        id: CHEBI:30621
        label: diarsenic trioxide

- name: ATRA plus ATO and Limited Idarubicin for High-Risk APL
  description: >-
    For newly diagnosed high-risk APL (presenting white-cell count above 10 ×
    10^9/L), APOLLO paired ATRA plus ATO with two idarubicin doses and improved
    two-year event-free survival relative to its anthracycline-based comparator;
    this is not a chemotherapy-free regimen. The 133-patient trial stopped early
    because of slow accrual during the COVID-19 pandemic, which limits precision.
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  regimen_term:
    preferred_term: Arsenic Trioxide/Idarubicin/Tretinoin Regimen
    term:
      id: NCIT:C198433
      label: Arsenic Trioxide/Idarubicin/Tretinoin Regimen
  target_mechanisms:
  - target: PML-RARA Corepressor Recruitment
    treatment_effect: INHIBITS
    description: ATRA relieves PML::RARA-mediated repression.
    evidence:
    - reference: PMID:34193815
      reference_title: Acute promyelocytic leukemia current treatment algorithms.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        ATRA causes a conformational change of the PML–RARA fusion transcripts,
        leading to the release of the co-repressors, recruitment of histone
        acetyltransferases, and relief of transcriptional repression
      explanation: This supports the ATRA component's mechanism.
  - target: PML Nuclear-Body Disassembly
    treatment_effect: INHIBITS
    description: ATO promotes PML::RARA degradation and nuclear-body reformation.
    evidence:
    - reference: PMID:37655965
      reference_title: Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Arsenic trioxide (ATO) cures 70% of patients with APL, driving PML-RARA
        degradation and NB reformation.
      explanation: This supports the ATO component's mechanism.
  evidence:
  - reference: PMID:34193815
    reference_title: Acute promyelocytic leukemia current treatment algorithms.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      A presentation WBC count greater than 10,000/µL represents high-risk APL.
    explanation: The treatment review defines the high-risk white-cell-count threshold used here.
  - reference: PMID:40825164
    reference_title: "Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Adult patients with newly diagnosed high-risk APL in the ATRA-ATO arm
      received ATO 0.15 mg/kg once daily and ATRA 45 mg/m2 twice daily until
      complete remission (CR), with two doses of idarubicin 12 mg/m2 on days 1
      and 3, followed by consolidation therapy (four ATRA-ATO cycles).
    explanation: The trial methods establish the ATRA-ATO strategy with limited idarubicin in high-risk APL.
  - reference: PMID:40825164
    reference_title: "Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      After a median follow-up of 37 months (range, 1.7-88.6 months), 2-year EFS
      was 88% in the ATRA-ATO arm and 71% in the ATRA-CHT arm
    explanation: The trial directly supports the reported event-free-survival advantage.
  - reference: PMID:40825164
    reference_title: "Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      As of July 2022, 133 eligible patients had received either ATRA-ATO (n = 68)
      or ATRA-CHT (n = 65). The study was discontinued prematurely because of slow
      accrual during the COVID-19 pandemic.
    explanation: The publication supports the cohort size and early-stop qualification.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: all-trans-retinoic acid
      term:
        id: CHEBI:15367
        label: all-trans-retinoic acid
    - preferred_term: arsenic trioxide
      term:
        id: CHEBI:30621
        label: diarsenic trioxide
    - preferred_term: idarubicin
      term:
        id: CHEBI:42068
        label: idarubicin

- name: Transfusion Support for APL Coagulopathy
  description: >-
    Begin blood-product support immediately when APL is suspected, alongside
    ATRA, and monitor platelets and coagulation parameters frequently during
    induction. Replace platelets, fibrinogen, and other coagulation factors to
    reduce bleeding risk. Targets vary among protocols; one published algorithm
    uses INR below 1.5-2.0, fibrinogen above 100 mg/dL, and platelets above
    30,000/µL rather than establishing a universal threshold for all settings.
  action_category: THERAPEUTIC
  therapeutic_modality: OTHER
  target_phenotypes:
  - preferred_term: Abnormal Bleeding
    term:
      id: HP:0001892
      label: Abnormal bleeding
  - preferred_term: Thrombocytopenia
    term:
      id: HP:0001873
      label: Thrombocytopenia
  evidence:
  - reference: PMID:34193815
    reference_title: Acute promyelocytic leukemia current treatment algorithms.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In addition to prompt ATRA administration, coagulopathy should be
      adequately corrected by keeping internationalized normalized ratio (INR)
      for PT at less than 1.5–2.0, fibrinogen greater than 100 mg/dL platelets
      greater than 30,000/µL through blood product transfusions.
    explanation: The review supports immediate correction alongside ATRA and gives one explicit protocol's targets.
  - reference: PMID:34193815
    reference_title: Acute promyelocytic leukemia current treatment algorithms.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Platelet counts and coagulation parameters, including PTT, PT, as well as
      fibrinogen levels, should be monitored daily to keep these parameters
      within range.
    explanation: The review supports frequent laboratory monitoring during correction of APL coagulopathy.
  - reference: PMID:33860520
    reference_title: Management of Disseminated Intravascular Coagulation in Acute Leukemias.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Other aspects of management focus on supportive care aimed at minimizing
      the risk of bleeding, via transfusion of blood products.
    explanation: The review supports transfusion-based supportive care while avoiding unsupported universal thresholds.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care

- name: Dexamethasone for Differentiation Syndrome
  description: >-
    Dexamethasone should be started promptly when differentiation syndrome is
    suspected; one treatment review recommends 10 mg every 12 hours until signs
    resolve or for at least three days. Holding ATRA or ATO is generally
    reserved for severe clinical deterioration rather than routine management.
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Differentiation Syndrome Inflammatory-Endothelial Response
    treatment_effect: INHIBITS
    description: Corticosteroid therapy suppresses the inflammatory response associated with the syndrome.
    evidence:
    - reference: PMID:24627526
      reference_title: How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        DS diagnosis should be suspected in the presence of any of the
        above-mentioned signs and symptoms, and preemptive treatment with
        dexamethasone should be started immediately.
      explanation: The review supports immediate dexamethasone treatment; the precise molecular target is inferred from corticosteroid action.
  evidence:
  - reference: PMID:34193815
    reference_title: Acute promyelocytic leukemia current treatment algorithms.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Dexamethasone 10 mg (every 12 hours) should be administered for the
      treatment of suspected or overt DS, until resolution of symptoms and signs
      or for a minimum of three days
    explanation: The treatment review supports the stated dexamethasone schedule.
  - reference: PMID:24627526
    reference_title: How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      DS diagnosis should be suspected in the presence of any of the
      above-mentioned signs and symptoms, and preemptive treatment with
      dexamethasone should be started immediately.
    explanation: The review directly supports prompt dexamethasone at clinical suspicion.
  - reference: PMID:24627526
    reference_title: How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Temporary discontinuation of all-trans retinoic acid or arsenic trioxide
      is indicated only for patients in very poor clinical condition or with
      severe renal or pulmonary dysfunction, sometimes requiring admission to
      the intensive care unit.
    explanation: The review limits temporary interruption of differentiating agents to severe clinical deterioration.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
    therapeutic_agent:
    - preferred_term: dexamethasone
      term:
        id: CHEBI:41879
        label: dexamethasone

clinical_trials:
- name: NCT00482833
  phase: PHASE_III
  status: COMPLETED
  description: >-
    APL0406 randomized low-to-intermediate-risk APL to ATRA plus ATO versus ATRA
    plus idarubicin-based chemotherapy and established the chemotherapy-free
    regimen's noninferiority, with superior event-free survival in the reported
    analysis.
  evidence:
  - reference: PMID:23841729
    reference_title: Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We conducted a phase 3, multicenter trial comparing ATRA plus chemotherapy
      with ATRA plus arsenic trioxide in patients with APL classified as
      low-to-intermediate risk (white-cell count, ≤10×10(9) per liter).
    explanation: The publication defines the completed phase III trial population and comparison.
  - reference: PMID:23841729
    reference_title: Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Two-year event-free survival rates were 97% in the ATRA-arsenic trioxide
      group and 86% in the ATRA-chemotherapy group
    explanation: The publication directly supports the superior event-free survival stated in the trial summary.
  - reference: PMID:23841729
    reference_title: Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ClinicalTrials.gov number, NCT00482833."
    explanation: The publication explicitly identifies ClinicalTrials.gov record NCT00482833.
- name: NCT02688140
  phase: PHASE_III
  status: COMPLETED
  description: >-
    APOLLO compared ATRA plus ATO with limited idarubicin against standard
    ATRA-anthracycline therapy in newly diagnosed high-risk APL.
  evidence:
  - reference: PMID:40825164
    reference_title: "Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      PURPOSE: The phase III APOLLO trial prospectively compared the efficacy of
      arsenic trioxide (ATO) in combination with all-trans retinoic acid (ATRA)
    explanation: The publication identifies APOLLO as a phase III comparison of the ATRA-ATO strategy.
  - reference: PMID:40825164
    reference_title: "Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      plus low-dose idarubicin versus standard ATRA plus anthracycline-based
      chemotherapy (ATRA-CHT) regimen (ie, ATRA and idarubicin regimen) in
      patients with high-risk acute promyelocytic leukemia (APL; EudraCT
      2015-01151-68; ClinicalTrials.gov identifier: NCT02688140).
    explanation: The publication supplies the comparator, high-risk population, and ClinicalTrials.gov identifier.

- name: NCT07503730
  phase: PHASE_III
  status: RECRUITING
  description: >-
    Multicenter randomized study testing whether adding oral
    Realgar-Indigo Naturalis Formula to immediate ATRA before molecular
    confirmation reduces 30-day early mortality in suspected APL.
  notes: ClinicalTrials.gov status checked 2026-07-16.
  evidence:
  - reference: clinicaltrials:NCT07503730
    reference_title: Multicenter, Randomized Controlled Clinical Study on Early Application of Realgar-Indigo Naturalis Formula (RIF) for Treatment of Acute Promyelocytic Leukemia (APL)
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This multicenter, randomized controlled trial evaluates whether early
      induction treatment with oral Realgar-Indigo Naturalis Formula (RIF)
      combined with all-trans retinoic acid (ATRA) reduces early death rates in
      patients with acute promyelocytic leukemia (APL).
    explanation: The current registry record supports the randomized early-intervention design and disease population.
  - reference: clinicaltrials:NCT07503730
    reference_title: Multicenter, Randomized Controlled Clinical Study on Early Application of Realgar-Indigo Naturalis Formula (RIF) for Treatment of Acute Promyelocytic Leukemia (APL)
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Experimental group: oral ATRA + RIF before molecular diagnosis confirmation"
    explanation: The registry directly supports starting the experimental combination before molecular confirmation.
  - reference: clinicaltrials:NCT07503730
    reference_title: Multicenter, Randomized Controlled Clinical Study on Early Application of Realgar-Indigo Naturalis Formula (RIF) for Treatment of Acute Promyelocytic Leukemia (APL)
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      To evaluate whether early induction with ATRA + RIF reduces early death
      rate (within 30 days of diagnosis) in APL patients.
    explanation: The registry directly supports the 30-day early-mortality endpoint.

- name: NCT07296445
  phase: PHASE_III
  status: NOT_RECRUITING
  description: >-
    LATITUDE is a randomized crossover study of oral versus intravenous arsenic
    trioxide during consolidation for newly diagnosed non-high-risk APL.
  notes: >-
    ClinicalTrials.gov reported NOT_YET_RECRUITING on 2026-07-16; the schema
    represents this as NOT_RECRUITING because it has no separate
    not-yet-recruiting value.
  evidence:
  - reference: clinicaltrials:NCT07296445
    reference_title: LATITUDE - A Phase 3, Randomized, Open-Label, 3-Cohort, 2-Period, 2-Sequence, Crossover Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of Oral Arsenic Trioxide Versus Intravenous Arsenic Trioxide for Consolidation Therapy in Participants With Newly Diagnosed, Non-High-Risk, Acute Promyelocytic Leukemia
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      LATITUDE: A Phase 3, Randomized, Open-Label, 3-Cohort,
      2-Period, 2-Sequence, Crossover Trial to Evaluate the Pharmacokinetics, Safety, and
      Efficacy of Oral Arsenic Trioxide Versus Intravenous Arsenic Trioxide for
      Consolidation Therapy in Participants With Newly Diagnosed, Non-High Risk,
      Acute Promyelocytic Leukemia
    explanation: The current registry record supports the phase III oral-versus-intravenous consolidation comparison.

- name: NCT01409161
  phase: PHASE_II
  status: RECRUITING
  description: >-
    Phase II study of ATRA plus ATO with or without gemtuzumab ozogamicin in
    previously untreated APL.
  notes: ClinicalTrials.gov status checked 2026-07-16.
  evidence:
  - reference: clinicaltrials:NCT01409161
    reference_title: Phase II Study of Treatment of Acute Promyelocytic Leukemia (APL) With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin (GO)
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This phase II trial studies how well tretinoin and arsenic trioxide with or
      without gemtuzumab ozogamicin works in treating patients with previously
      untreated acute promyelocytic leukemia.
    explanation: The current registry record supports the phase II regimen and untreated-APL population.

- name: NCT06982274
  phase: PHASE_II
  status: RECRUITING
  description: >-
    International Consortium on APL study of oral arsenic plus ATRA, adding
    minimal-dose chemotherapy for high-risk newly diagnosed disease.
  notes: ClinicalTrials.gov status checked 2026-07-16.
  evidence:
  - reference: clinicaltrials:NCT06982274
    reference_title: "Combination of Oral Arsenic With ATRA and Minimal-Dose Chemotherapy for Newly Diagnosed Patients With Acute Promyelocytic Leukemia: a Study by the International Consortium on APL"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It is a non-randomized, multicenter, prospective study, aiming to treat
      patients with newly diagnosed acute promyelocytic leukemia with a
      combination of oral arsenic and atra, with low dose chemotherapy for those
      with high-risk disease (white blood cell count above 10x10a9/L).
    explanation: The current registry record supports the oral-arsenic strategy and risk-adapted chemotherapy component.

- name: NCT07187505
  phase: NOT_APPLICABLE
  status: ACTIVE_NOT_RECRUITING
  description: >-
    Prospective single-arm study of venetoclax added to ATRA and ATO for newly
    diagnosed APL with hyperleukocytosis.
  notes: >-
    ClinicalTrials.gov did not assign a conventional phase and reported
    ACTIVE_NOT_RECRUITING on 2026-07-16.
  evidence:
  - reference: clinicaltrials:NCT07187505
    reference_title: "Venetoclax Plus All-Trans Retinoic Acid and Arsenic Trioxide in Newly Diagnosed Acute Promyelocytic Leukemia With Hyperleukocytosis: A Prospective Single-Arm Study"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This study aims to evaluate the safety and effectiveness of combining
      venetoclax with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO)
      in patients with newly diagnosed acute promyelocytic leukemia (APL) who
      have very high white blood cell counts.
    explanation: The current registry record supports the hyperleukocytic-APL combination study.

discussions:
- discussion_id: gap_apl_cooperating_lesions
  prompt: >-
    Which cooperating somatic lesions determine progression from a
    PML::RARA-initiated preleukemic state to overt APL, and which of those
    lesions materially shape relapse or treatment resistance in humans?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Somatic PML-RARA Fusion
  - genetic#FLT3
  rationale: >-
    PML::RARA transgenic mice show a long-latency, incompletely penetrant
    disease, whereas FLT3-ITD markedly accelerates an APL-like phenotype. This
    proves that cooperation can matter experimentally but does not establish a
    complete human progression or resistance map.
  evidence:
  - reference: PMID:9122233
    reference_title: A PMLRARalpha transgene initiates murine acute promyelocytic leukemia.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      PMLRAR alpha transgenic mice exhibited impaired neutrophil maturation
      early in life, which progressed at a low frequency over the course of
      several months to overt APL.
    explanation: Low-frequency, long-latency progression motivates the search for cooperating lesions.
  - reference: PMID:12060771
    reference_title: PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      These observations document cooperation between PML/RARalpha and FLT3-ITD
      in development of the murine APL phenotype.
    explanation: FLT3-ITD demonstrates one experimentally validated cooperation route.

disease_term:
  preferred_term: acute promyelocytic leukemia
  term:
    id: MONDO:0012883
    label: acute promyelocytic leukemia

classifications:
  icdo_morphology:
    classification_value: Leukemia
    evidence:
    - reference: DOI:10.3390/cancers16071351
      reference_title: History of Developing Acute Promyelocytic Leukemia Treatment and Role of Promyelocytic Leukemia Bodies
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        The story of acute promyelocytic leukemia (APL) discovery,
        physiopathology, and treatment is a unique journey, transforming the
        most aggressive form of leukemia to the most curable.
      explanation: The review identifies APL as a leukemia, supporting the morphology-axis classification.
  harrisons_chapter:
  - classification_value: ONCOLOGY_HEMATOLOGY
    evidence:
    - reference: DOI:10.3390/cancers16071351
      reference_title: History of Developing Acute Promyelocytic Leukemia Treatment and Role of Promyelocytic Leukemia Bodies
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        The story of acute promyelocytic leukemia (APL) discovery,
        physiopathology, and treatment is a unique journey, transforming the
        most aggressive form of leukemia to the most curable.
      explanation: APL is a hematologic malignancy within oncology and hematology.
references:
- reference: clinicaltrials:NCT01409161
  title: Phase II Study of Treatment of Acute Promyelocytic Leukemia (APL) With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin (GO)
- reference: clinicaltrials:NCT06982274
  title: "Combination of Oral Arsenic With ATRA and Minimal-Dose Chemotherapy for Newly Diagnosed Patients With Acute Promyelocytic Leukemia: a Study by the International Consortium on APL"
- reference: clinicaltrials:NCT07187505
  title: "Venetoclax Plus All-Trans Retinoic Acid and Arsenic Trioxide in Newly Diagnosed Acute Promyelocytic Leukemia With Hyperleukocytosis: A Prospective Single-Arm Study"
- reference: clinicaltrials:NCT07296445
  title: LATITUDE - A Phase 3, Randomized, Open-Label, 3-Cohort, 2-Period, 2-Sequence, Crossover Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of Oral Arsenic Trioxide Versus Intravenous Arsenic Trioxide for Consolidation Therapy in Participants With Newly Diagnosed, Non-High-Risk, Acute Promyelocytic Leukemia
- reference: clinicaltrials:NCT07503730
  title: Multicenter, Randomized Controlled Clinical Study on Early Application of Realgar-Indigo Naturalis Formula (RIF) for Treatment of Acute Promyelocytic Leukemia (APL)
- reference: ORPHA:520
  title: Acute promyelocytic leukemia
- reference: DOI:10.3390/cancers16061160
  title: "Acute Promyelocytic Leukemia: Review of Complications Related to All-Trans Retinoic Acid and Arsenic Trioxide Therapy"
- reference: DOI:10.3390/cancers16071351
  title: History of Developing Acute Promyelocytic Leukemia Treatment and Role of Promyelocytic Leukemia Bodies
- reference: DOI:10.3390/cancers16183208
  title: "MRD in Acute Leukemias: Lessons Learned from Acute Promyelocytic Leukemia"
- reference: DOI:10.3390/cancers16244192
  title: "Acute Promyelocytic Leukemia-like AML: Genetic Perspective and Clinical Implications"
- reference: PMID:397771
  title: "Acute promyelocytic leukemia."
- reference: PMID:9122233
  title: A PMLRARalpha transgene initiates murine acute promyelocytic leukemia.
- reference: PMID:12060771
  title: PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model.
- reference: PMID:16352814
  title: ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression.
- reference: PMID:22220256
  title: "The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature."
- reference: PMID:22535601
  title: "Acute promyelocytic leukemia: four distinct patterns by flow cytometry immunophenotyping."
- reference: PMID:23841729
  title: Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
- reference: PMID:24344243
  title: "Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia."
- reference: PMID:24627526
  title: How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia.
- reference: PMID:26088929
  title: Transcription and methylation analyses of preleukemic promyelocytes indicate a dual role for PML/RARA in leukemia initiation.
- reference: PMID:33860520
  title: Management of Disseminated Intravascular Coagulation in Acute Leukemias.
- reference: PMID:34193815
  title: Acute promyelocytic leukemia current treatment algorithms.
- reference: PMID:36539954
  title: Association between FLT3-ITD and additional chromosomal abnormalities in the prognosis of acute promyelocytic leukemia.
- reference: PMID:37444587
  title: "The Coagulopathy of Acute Promyelocytic Leukemia: An Updated Review of Pathophysiology, Risk Stratification, and Clinical Management."
- reference: PMID:37655965
  title: Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function.
- reference: PMID:38503502
  title: "Acute Promyelocytic Leukemia, Retinoic Acid, and Arsenic: A Tale of Dualities."
- reference: PMID:38890097
  title: "Diagnosis and management of acute promyelocytic leukemia: Brazilian consensus guidelines 2024 on behalf of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy."
- reference: PMID:39858554
  title: "Utilization of RT-PCR and Optical Genome Mapping in Acute Promyelocytic Leukemia with Cryptic PML::RARA Rearrangement: A Case Discussion and Systemic Literature Review."
- reference: PMID:40825164
  title: "Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial."
📚

References & Deep Research

References

29
clinicaltrials:NCT01409161
Phase II Study of Treatment of Acute Promyelocytic Leukemia (APL) With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin (GO)
No top-level findings curated for this source.
clinicaltrials:NCT06982274
Combination of Oral Arsenic With ATRA and Minimal-Dose Chemotherapy for Newly Diagnosed Patients With Acute Promyelocytic Leukemia: a Study by the International Consortium on APL
No top-level findings curated for this source.
clinicaltrials:NCT07187505
Venetoclax Plus All-Trans Retinoic Acid and Arsenic Trioxide in Newly Diagnosed Acute Promyelocytic Leukemia With Hyperleukocytosis: A Prospective Single-Arm Study
No top-level findings curated for this source.
clinicaltrials:NCT07296445
LATITUDE - A Phase 3, Randomized, Open-Label, 3-Cohort, 2-Period, 2-Sequence, Crossover Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of Oral Arsenic Trioxide Versus Intravenous Arsenic Trioxide for Consolidation Therapy in Participants With Newly Diagnosed, Non-High-Risk, Acute Promyelocytic Leukemia
No top-level findings curated for this source.
clinicaltrials:NCT07503730
Multicenter, Randomized Controlled Clinical Study on Early Application of Realgar-Indigo Naturalis Formula (RIF) for Treatment of Acute Promyelocytic Leukemia (APL)
No top-level findings curated for this source.
ORPHA:520
Acute promyelocytic leukemia
No top-level findings curated for this source.
DOI:10.3390/cancers16061160
Acute Promyelocytic Leukemia: Review of Complications Related to All-Trans Retinoic Acid and Arsenic Trioxide Therapy
No top-level findings curated for this source.
DOI:10.3390/cancers16071351
History of Developing Acute Promyelocytic Leukemia Treatment and Role of Promyelocytic Leukemia Bodies
No top-level findings curated for this source.
DOI:10.3390/cancers16183208
MRD in Acute Leukemias: Lessons Learned from Acute Promyelocytic Leukemia
No top-level findings curated for this source.
DOI:10.3390/cancers16244192
Acute Promyelocytic Leukemia-like AML: Genetic Perspective and Clinical Implications
No top-level findings curated for this source.
PMID:397771
Acute promyelocytic leukemia.
No top-level findings curated for this source.
PMID:9122233
A PMLRARalpha transgene initiates murine acute promyelocytic leukemia.
No top-level findings curated for this source.
PMID:12060771
PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model.
No top-level findings curated for this source.
PMID:16352814
ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression.
No top-level findings curated for this source.
PMID:22220256
The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature.
No top-level findings curated for this source.
PMID:22535601
Acute promyelocytic leukemia: four distinct patterns by flow cytometry immunophenotyping.
No top-level findings curated for this source.
PMID:23841729
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
No top-level findings curated for this source.
PMID:24344243
Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia.
No top-level findings curated for this source.
PMID:24627526
How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia.
No top-level findings curated for this source.
PMID:26088929
Transcription and methylation analyses of preleukemic promyelocytes indicate a dual role for PML/RARA in leukemia initiation.
No top-level findings curated for this source.
PMID:33860520
Management of Disseminated Intravascular Coagulation in Acute Leukemias.
No top-level findings curated for this source.
PMID:34193815
Acute promyelocytic leukemia current treatment algorithms.
No top-level findings curated for this source.
PMID:36539954
Association between FLT3-ITD and additional chromosomal abnormalities in the prognosis of acute promyelocytic leukemia.
No top-level findings curated for this source.
PMID:37444587
The Coagulopathy of Acute Promyelocytic Leukemia: An Updated Review of Pathophysiology, Risk Stratification, and Clinical Management.
No top-level findings curated for this source.
PMID:37655965
Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function.
No top-level findings curated for this source.
PMID:38503502
Acute Promyelocytic Leukemia, Retinoic Acid, and Arsenic: A Tale of Dualities.
No top-level findings curated for this source.
PMID:38890097
Diagnosis and management of acute promyelocytic leukemia: Brazilian consensus guidelines 2024 on behalf of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy.
No top-level findings curated for this source.
PMID:39858554
Utilization of RT-PCR and Optical Genome Mapping in Acute Promyelocytic Leukemia with Cryptic PML::RARA Rearrangement: A Case Discussion and Systemic Literature Review.
No top-level findings curated for this source.
PMID:40825164
Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.
No top-level findings curated for this source.

Deep Research

2
Falcon ▸
Acute Promyelocytic Leukemia (APL) with PML::RARA fusion — Disease Characteristics Research Report
Edison Scientific Literature 26 citations 2026-04-05T12:00:24.489449

Acute Promyelocytic Leukemia (APL) with PML::RARA fusion — Disease Characteristics Research Report

Target disease: Acute promyelocytic leukemia (APL) driven by the PML::RARA fusion (canonical t(15;17)).
Category: Genetically defined subtype of acute myeloid leukemia (AML). (iyer2023thetreatmentof pages 1-2, guarnera2024acutepromyelocyticleukemialike pages 1-2)

Field Value Evidence/source (author-year) PMID/DOI/URL when available
Disease name Acute promyelocytic leukemia (APL), PML::RARA Iyer et al. 2023; Gill et al. 2023 (iyer2023thetreatmentof pages 1-2, gill2023acutepromyelocyticleukaemia pages 1-2) DOI: 10.3389/fonc.2022.1062524; https://doi.org/10.3389/fonc.2022.1062524 ; DOI: 10.1186/s12885-023-10612-z; https://doi.org/10.1186/s12885-023-10612-z
Synonyms / alternative names APL; acute promyelocytic leukaemia; FAB AML-M3; PML-RARα / PML::RARA-positive APL Almeida et al. 2023; Guarnera et al. 2024 (almeida2023acutepromyelocyticleukemia pages 1-2, guarnera2024acutepromyelocyticleukemialike pages 1-2) DOI: 10.3390/futurepharmacol3010012; https://doi.org/10.3390/futurepharmacol3010012 ; DOI: 10.3390/cancers16244192; https://doi.org/10.3390/cancers16244192
Category Acute myeloid leukemia (AML) subtype / genetically defined AML with recurrent fusion Iyer et al. 2023; Guarnera et al. 2024 (iyer2023thetreatmentof pages 1-2, guarnera2024acutepromyelocyticleukemialike pages 1-2) DOI: 10.3389/fonc.2022.1062524; https://doi.org/10.3389/fonc.2022.1062524 ; DOI: 10.3390/cancers16244192; https://doi.org/10.3390/cancers16244192
Key molecular lesion Balanced translocation t(15;17) generating PML::RARA fusion; fusion acts as a transcriptional repressor, blocks myeloid differentiation, and disrupts PML nuclear bodies Iyer et al. 2023; Bercier & de Thé 2024 (iyer2023thetreatmentof pages 1-2, bercier2024historyofdeveloping pages 4-6) DOI: 10.3389/fonc.2022.1062524; https://doi.org/10.3389/fonc.2022.1062524 ; DOI: 10.3390/cancers16071351; https://doi.org/10.3390/cancers16071351
Variants / related fusions Rare APL-like RARA fusion variants exist (e.g., PLZF::RARA / ZBTB16::RARA and other non-PML RARA fusions); some are ATO-insensitive and diagnostically important mimics Guarnera et al. 2024; Bercier & de Thé 2024 (guarnera2024acutepromyelocyticleukemialike pages 1-2, bercier2024historyofdeveloping pages 6-7) DOI: 10.3390/cancers16244192; https://doi.org/10.3390/cancers16244192 ; DOI: 10.3390/cancers16071351; https://doi.org/10.3390/cancers16071351
Key identifiers supported in context ICD-10: C92.4 Matsuda et al. 2022 (not a context ID source for disease biology, but present in retrieved evidence); leave unsupported identifiers blank in this artifact context. Within context IDs, no MONDO/OMIM/Orphanet code was directly supported. (gill2023acutepromyelocyticleukaemia pages 1-2, iyer2023thetreatmentof pages 1-2) ICD-10 C92.4 referenced in retrieved literature; disease-level context IDs do not provide additional identifier codes
Epidemiology: proportion of AML ~10% of AML; also reported as ~15% of AML; review of European incidence notes 8–15% of AML Ghiaur et al. 2024; Iyer et al. 2023; Guarnera et al. 2024 (ghiaur2024acutepromyelocyticleukemia pages 1-2, iyer2023thetreatmentof pages 1-2, guarnera2024acutepromyelocyticleukemialike pages 1-2) DOI: 10.3390/cancers16061160; https://doi.org/10.3390/cancers16061160 ; DOI: 10.3389/fonc.2022.1062524; https://doi.org/10.3389/fonc.2022.1062524 ; DOI: 10.3390/cancers16244192; https://doi.org/10.3390/cancers16244192
Epidemiology: incidence Population-based annual incidence averaged 0.32 per 100,000 in Hong Kong cohort; European review cited incidence of 0.12 per 100,000 person-years Gill et al. 2023; Guarnera et al. 2024 (gill2023acutepromyelocyticleukaemia pages 1-2, guarnera2024acutepromyelocyticleukemialike pages 1-2) DOI: 10.1186/s12885-023-10612-z; https://doi.org/10.1186/s12885-023-10612-z ; DOI: 10.3390/cancers16244192; https://doi.org/10.3390/cancers16244192
Hallmark complication: coagulopathy / DIC / bleeding Characteristic aggressive coagulopathy with DIC and primary hyperfibrinolysis; severe hemorrhagic syndrome is a major cause of early death, often involving cerebral or pulmonary bleeding Iyer et al. 2023; Almeida et al. 2023; Gill et al. 2023 (iyer2023thetreatmentof pages 1-2, almeida2023acutepromyelocyticleukemia pages 1-2, gill2023acutepromyelocyticleukaemia pages 1-2) DOI: 10.3389/fonc.2022.1062524; https://doi.org/10.3389/fonc.2022.1062524 ; DOI: 10.3390/futurepharmacol3010012; https://doi.org/10.3390/futurepharmacol3010012 ; DOI: 10.1186/s12885-023-10612-z; https://doi.org/10.1186/s12885-023-10612-z
Hallmark complication: differentiation syndrome Important treatment-related inflammatory/vasoactive syndrome during differentiation therapy (ATRA/ATO); associated with leukocytosis and can contribute to early morbidity/mortality if not rapidly recognized and treated Iyer et al. 2023; Ghiaur et al. 2024 (iyer2023thetreatmentof pages 2-4, ghiaur2024acutepromyelocyticleukemia pages 1-2) DOI: 10.3389/fonc.2022.1062524; https://doi.org/10.3389/fonc.2022.1062524 ; DOI: 10.3390/cancers16061160; https://doi.org/10.3390/cancers16061160
Early death context Early death remains the major obstacle to cure; real-world studies reported 30-day/very-early death burdens, including 144 early deaths in a 1991–2021 population cohort and 12.5% 7-day early death in a single-center cohort Gill et al. 2023; Infante et al. 2023 (gill2023acutepromyelocyticleukaemia pages 1-2) DOI: 10.1186/s12885-023-10612-z; https://doi.org/10.1186/s12885-023-10612-z ; DOI: 10.1007/s00277-023-05422-z; https://doi.org/10.1007/s00277-023-05422-z

Table: This table condenses the core disease-definition, molecular, epidemiologic, identifier, and complication facts for acute promyelocytic leukemia with PML::RARA. It is useful as a quick-reference artifact for populating disease knowledge-base summary fields.

1. Disease information

Overview (what is the disease?)

Acute promyelocytic leukemia (APL) is an AML subtype defined in most cases by a balanced t(15;17) chromosomal translocation that creates the PML::RARA fusion oncoprotein. This fusion enforces a differentiation block at the promyelocyte stage and is associated with a distinctive, high-risk hemorrhagic/coagulopathic presentation. (iyer2023thetreatmentof pages 1-2, bercier2024historyofdeveloping pages 4-6, gill2023acutepromyelocyticleukaemia pages 1-2)

Common synonyms and alternative names

Commonly used names include acute promyelocytic leukemia, acute promyelocytic leukaemia, APL, FAB AML-M3, and PML-RARα / PML::RARA-positive APL. (almeida2023acutepromyelocyticleukemia pages 1-2, guarnera2024acutepromyelocyticleukemialike pages 1-2)

Key identifiers and classification systems

  • ICD-10: C92.4 (acute promyelocytic leukemia) is used in real-world health services research for APL. (guarnera2024acutepromyelocyticleukemialike pages 1-2)
  • Molecular hallmark: PML::RARA fusion transcript. (iyer2023thetreatmentof pages 1-2, ghiaur2024acutepromyelocyticleukemia pages 1-2)
  • MONDO / Orphanet / OMIM / MeSH: Not directly extractable from the retrieved full-text evidence in this run; therefore not asserted here.

Evidence source type

The available evidence includes (i) aggregated disease-level resources (reviews), (ii) population-based outcomes research (registry/cohort), and (iii) mechanistic primary research (cell/mouse/xenograft models). (iyer2023thetreatmentof pages 1-2, gill2023acutepromyelocyticleukaemia pages 1-2, dai2023targetinghdac3to pages 1-2)

2. Etiology

Disease causal factors (genetic/mechanistic)

The primary causal lesion in classical APL is the PML::RARA fusion generated by t(15;17), which acts as a dominant-negative regulator of retinoic acid receptor signaling and disrupts PML nuclear bodies, producing a differentiation block. (bercier2024historyofdeveloping pages 4-6, guarnera2024acutepromyelocyticleukemialike pages 1-2)

Risk factors

Robust, population-level external risk factors (environmental/lifestyle) were not identifiable from the retrieved evidence.

However, several studies highlight presentation severity features that act as strong clinical risk factors for early mortality (a major outcome determinant): * Leukocytosis/high WBC is repeatedly linked to higher early death risk in population-based and real-world cohorts. (gill2023acutepromyelocyticleukaemia pages 1-2, iyer2023thetreatmentof pages 2-4) * A real-world cohort focusing on very early death reported associations with DIC score severity and elevated creatinine (independent predictor of 7‑day ED). (guarnera2024acutepromyelocyticleukemialike pages 1-2)

Protective factors

No specific protective genetic or environmental factors were extractable from the retrieved evidence.

Gene–environment interactions

No direct gene–environment interaction evidence was extractable from the retrieved evidence.

3. Phenotypes

Core clinical phenotypes (human clinical)

APL typically presents as an acute leukemia with cytopenias plus a prominent thrombo-hemorrhagic diathesis driven by severe coagulopathy, often described as DIC with hyperfibrinolysis. (iyer2023thetreatmentof pages 1-2, almeida2023acutepromyelocyticleukemia pages 1-2)

Key clinical manifestations and laboratory abnormalities supported by the retrieved evidence: * Coagulopathy / DIC / hyperfibrinolysis → major driver of early death. (iyer2023thetreatmentof pages 1-2, gill2023acutepromyelocyticleukaemia pages 1-2) * Severe hemorrhage, often intracranial and pulmonary in reports/reviews. (almeida2023acutepromyelocyticleukemia pages 1-2) * Differentiation syndrome (DS) as a treatment complication during differentiation therapy (ATRA/ATO), described as systemic inflammatory/vasoactive syndrome and included among causes of early morbidity/mortality. (iyer2023thetreatmentof pages 2-4, ghiaur2024acutepromyelocyticleukemia pages 1-2) * Typical immunophenotype (supporting diagnosis): commonly CD33+, CD13+, HLA‑DR negative, and often low-frequency CD34 expression. (guarnera2024acutepromyelocyticleukemialike pages 1-2)

Phenotype characteristics

  • Temporal profile: onset is typically acute/subacute (acute leukemia presentation); early deaths cluster within the first days to 30 days after diagnosis, highlighting the time-critical nature of supportive care and prompt ATRA initiation. (iyer2023thetreatmentof pages 1-2, gill2023acutepromyelocyticleukaemia pages 1-2)
  • Frequency/importance: coagulopathy is consistently described as a hallmark feature and leading cause of early death. (iyer2023thetreatmentof pages 1-2, guarnera2024acutepromyelocyticleukemialike pages 1-2)

Quality of life impact

Direct QoL instrument results (e.g., EQ‑5D, SF‑36, PROMIS) were not extractable from the retrieved evidence; however, real-world reviews emphasize that early mortality and acute complications can prevent patients from receiving curative therapy, and that treatment toxicities (QT prolongation, hepatic toxicity, neurotoxicity, DS) require close monitoring. (ghiaur2024acutepromyelocyticleukemia pages 1-2, guarnera2024acutepromyelocyticleukemialike pages 1-2)

Suggested HPO terms (examples; mapping suggestions)

  • Disseminated intravascular coagulation (HP:0001979)
  • Thrombocytopenia (HP:0001873)
  • Hemorrhage (HP:0001892) / Intracranial hemorrhage (HP:0002170)
  • Hyperfibrinolysis (HP:0003253; if used)
  • Leukocytosis (HP:0001974) / Hyperleukocytosis (HP:0001974 with qualifier)
  • Acute myeloid leukemia (HP:0004808)
  • Differentiation syndrome (not consistently represented as a single HPO term in all releases; may require synonym mapping)

4. Genetic / molecular information

Causal genes and chromosomal abnormalities

  • Causal fusion: PML::RARA (PML fused to retinoic acid receptor alpha, RARA) created by t(15;17). (bercier2024historyofdeveloping pages 4-6, iyer2023thetreatmentof pages 1-2)
  • Disease definition: the PML::RARA fusion is described as the hallmark/defining lesion and therapeutic target of ATRA and ATO. (ghiaur2024acutepromyelocyticleukemia pages 1-2)

Variant fusions / molecular heterogeneity

Non-canonical RARA fusion partners (often termed “APL-like AML”) are rare but clinically critical because some are less sensitive/insensitive to arsenic-based therapy; a 2024 review summarizes that these entities are diagnostically challenging and heterogeneous. (guarnera2024acutepromyelocyticleukemialike pages 1-2, bercier2024historyofdeveloping pages 6-7)

Somatic co-mutations (modifiers)

A 2024 MRD-focused review notes that co-mutations such as FLT3, WT1, NRAS, KRAS occur and may affect prognosis, supporting broader molecular profiling beyond the fusion transcript in some contexts. (kegyes2024mrdinacute pages 6-7)

Epigenetic / post-translational regulation relevant to therapy response

Primary mechanistic literature and reviews converge on a pathway where ATO binding to the PML moiety drives post-translational modifications (SUMOylation/ubiquitination) leading to fusion degradation: * A 2023 Cell Death & Differentiation study summarizes ATO-induced SUMOylation and ubiquitination of PML‑RARα (including roles for PIAS1 and RNF4) as central to its degradation, and proposes HDAC3 as a modulator of this degradative pathway (via PML‑RARα deacetylation affecting PIAS1-mediated SUMOylation). (dai2023targetinghdac3to pages 1-2) * A 2024 historical/mechanistic review emphasizes that PML nuclear bodies are hubs for post-translational modifications including SUMOylation and ubiquitination and are disrupted by PML‑RARA. (bercier2024historyofdeveloping pages 6-7)

Suggested GO terms (mechanism-related; examples)

  • GO:0003700 DNA-binding transcription factor activity (fusion TF behavior)
  • GO:0006355 regulation of transcription, DNA-templated (altered transcriptional programs)
  • GO:0032182 SUMOylation
  • GO:0016567 protein ubiquitination
  • GO:0030433 ubiquitin-dependent protein catabolic process
  • GO:0006915 apoptosis (ATO dose-dependent apoptosis)
  • GO:0030154 cell differentiation (ATRA-induced granulocytic differentiation)

5. Environmental information

No specific environmental or infectious etiologic agents were extractable from the retrieved evidence.

6. Mechanism / pathophysiology

Causal chain (current understanding)

1) Initiating lesion: t(15;17) generates PML::RARA. (bercier2024historyofdeveloping pages 4-6, iyer2023thetreatmentof pages 1-2)
2) Nuclear/transcriptional effects: the fusion represses RARA target gene programs and disrupts PML nuclear bodies, leading to blocked granulocytic differentiation and abnormal promyelocyte accumulation. (guarnera2024acutepromyelocyticleukemialike pages 1-2, bercier2024historyofdeveloping pages 4-6)
3) System-level clinical phenotype: the leukemia has a characteristic coagulopathy/DIC and bleeding phenotype responsible for high early mortality without immediate recognition and treatment. (iyer2023thetreatmentof pages 1-2, gill2023acutepromyelocyticleukaemia pages 1-2)
4) Therapeutic mechanism (differentiation therapy): ATRA and ATO directly target the molecular lesion and associated nuclear structures: * ATRA relieves PML‑RARA–driven transcriptional repression and promotes terminal differentiation. (bercier2024historyofdeveloping pages 4-6, dai2023targetinghdac3to pages 1-2) * ATO binds the PML component and promotes post-translational modification cascades that drive PML‑RARA degradation and restoration of functional PML nuclear bodies. (dai2023targetinghdac3to pages 1-2, bercier2024historyofdeveloping pages 6-7)

Cellular processes / pathways highlighted by authoritative sources

A 2024 review describing “classic” APL biology states that PML::RARA “represses the transcription of RARa target genes and disrupts PML nuclear bodies, with subsequent impairment of differentiation, self-renewal, and response to DNA damage.” (guarnera2024acutepromyelocyticleukemialike pages 1-2)

Cell types (suggested CL terms)

  • Promyelocyte (CL:0000576) — malignant differentiation-arrested population
  • Myeloid progenitor cell (e.g., CL:0000763 for myeloid progenitor)
  • Granulocyte / neutrophil lineage cells (CL:0000775; mature differentiation outcome)

7. Anatomical structures affected

Primary organs/systems

APL is a hematologic malignancy primarily involving bone marrow and peripheral blood, with secondary system involvement driven by coagulopathy/bleeding (e.g., central nervous system hemorrhage) and treatment complications. (gill2023acutepromyelocyticleukaemia pages 1-2, almeida2023acutepromyelocyticleukemia pages 1-2)

Suggested UBERON terms

  • Bone marrow (UBERON:0002371)
  • Blood (UBERON:0000178)
  • Brain (UBERON:0000955) — relevant due to intracranial hemorrhage emphasis

Subcellular localization

Key disease biology centers on nuclear bodies (PML nuclear bodies) and nuclear transcriptional regulation. (bercier2024historyofdeveloping pages 6-7, guarnera2024acutepromyelocyticleukemialike pages 1-2)

8. Temporal development

Onset and progression

Disease onset is acute, with clinically important outcomes (especially hemorrhagic deaths) occurring early after presentation/diagnosis if ATRA and supportive care are delayed. A treatment review explicitly highlights “high risk of early death without prompt initiation of treatment at first clinical suspicion.” (iyer2023thetreatmentof pages 1-2)

Stages/course

A clinically meaningful “stage-like” construct used in practice is risk stratification by presenting WBC (and historically platelets) (e.g., WBC >10×10^9/L classified as high-risk in many schemas), which correlates with early death risk and guides intensity/adjunctive cytoreduction. (iyer2023thetreatmentof pages 2-4)

9. Inheritance and population

Inheritance pattern

APL (PML::RARA) is a somatic fusion-driven leukemia; germline Mendelian inheritance is not supported by the retrieved evidence.

Epidemiology (incidence; demographic notes)

  • Incidence: A population-based study (1991–2021) reported annual incidence averaging 0.32 per 100,000 in its population. (gill2023acutepromyelocyticleukaemia pages 1-2)
  • A 2024 review reports APL accounts for 8–15% of AML and cites a European incidence estimate of 0.12 per 100,000 person-years. (guarnera2024acutepromyelocyticleukemialike pages 1-2)
  • Age/sex in the population-based cohort: median age 44 years (range 1–97); 374 males/387 females. (gill2023acutepromyelocyticleukaemia pages 1-2)

10. Diagnostics

Diagnostic concept

APL is a time-critical diagnosis because its defining biology creates a high immediate risk of fatal hemorrhage. Molecular confirmation is recommended, but treatment is emphasized as urgent when APL is suspected clinically. (iyer2023thetreatmentof pages 1-2, bercier2024historyofdeveloping pages 4-6)

Clinical/pathology tests

  • Morphology: promyelocyte accumulation in blood/marrow; may show Auer rods. (bercier2024historyofdeveloping pages 4-6)
  • Flow cytometry phenotype: often CD33+/CD13+, HLA‑DR negative, low-frequency CD34 expression. (guarnera2024acutepromyelocyticleukemialike pages 1-2)

Genetic/molecular diagnostics

  • RT-PCR / real-time quantitative PCR (RQ-PCR) for detection of the APL-specific PML::RARA lesion is described as a route to rapid molecular confirmation, and is used for MRD monitoring in at least high-risk patients. (bercier2024historyofdeveloping pages 4-6)
  • Population-based studies report use of karyotype plus RT-PCR for PML‑RARA for confirmation. (gill2023acutepromyelocyticleukaemia pages 1-2)

MRD (measurable residual disease)

  • PCR-based detection of PML‑RARA in remission can anticipate relapse; a 2024 MRD review notes that RT-PCR positivity can precede morphologic relapse by 1–4 months and that “molecular relapse” emerged from this predictive capacity. (kegyes2024mrdinacute pages 6-7)
  • A treatment review cautions that “a positive PML‑RARA PCR at count recovery does not necessarily portend resistant disease,” emphasizing interpretation in context of timing/clinical course. (iyer2023thetreatmentof pages 2-4)

11. Outcome / prognosis

Modern curability contrasted with early-death risk

A 2023 treatment review states in its abstract that APL has been transformed into a “highly curable cancer with long-term survival exceeding 90%,” but also emphasizes that early death remains a major risk without rapid therapy. (iyer2023thetreatmentof pages 1-2)

Real-world outcomes and early mortality statistics

  • In a population-based cohort (1991–2021), there were 144 early deaths (defined as first 30 days), with early deaths “almost exclusively” occurring in ATRA-based inductions (139/144); overall 5-year and 10-year OS were 68.1% and 63.3%, while post‑30‑day OS was 84.0% and 78.1%. (gill2023acutepromyelocyticleukaemia pages 1-2)
  • Real-world observational work on very early death emphasizes the contribution of coagulopathy severity (DIC scores) to deaths before treatment initiation and within the first 7 days. (guarnera2024acutepromyelocyticleukemialike pages 1-2)

12. Treatment

Treatment principles (current standard concept)

APL is the paradigm of molecularly targeted differentiation therapy: all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) are directed at the PML::RARA-driven state and have enabled “chemotherapy-free” curative strategies for many patients. (iyer2023thetreatmentof pages 1-2, ghiaur2024acutepromyelocyticleukemia pages 1-2)

A 2024 review of ATRA/ATO complications states that the PML::RARA fusion is the molecular target of ATRA and ATO and that ATRA+ATO achieves “deep and durable molecular responses with a very low incidence of relapse,” while requiring monitoring for DS, hepatotoxicity, QT prolongation, and neurotoxicity. (ghiaur2024acutepromyelocyticleukemia pages 1-2)

Key regimens and reported outcomes (selected evidence-based statistics)

  • ATRA- plus oral-ATO-based regimens in a population program: In a 1991–2021 population-based study where oral-ATO-based regimens were implemented from 2013, oral-ATO use was associated with fewer early deaths and superior survival outcomes compared with earlier eras; reported incidence and survival statistics are summarized above. (gill2023acutepromyelocyticleukaemia pages 1-2)
  • Chemotherapy-free strategies in all-risk settings: A randomized phase III non-inferiority study reported complete remission 97% in both ATRA‑ATO and ATRA‑ATO+chemotherapy arms; 2‑year DFS 98% vs 97% and EFS 95% vs 92% (all-risk); high-risk subgroup DFS 94% vs 87% and EFS 85% vs 78%. (guarnera2024acutepromyelocyticleukemialike pages 1-2)

Supportive care implications (real-world implementation)

Population-based and real-world reviews emphasize that the gap between trial outcomes and real-world outcomes is largely driven by early mortality, delays in diagnosis/treatment, and variable expertise/resources for managing coagulopathy and complications. (guarnera2024acutepromyelocyticleukemialike pages 1-2, gill2023acutepromyelocyticleukaemia pages 1-2)

Treatment complications

A dedicated complications review highlights that ATRA/ATO therapy, while less hematologically toxic than chemotherapy, can cause differentiation syndrome, liver toxicity, QT interval prolongation, and neurotoxicity, requiring “rigorous monitoring.” (ghiaur2024acutepromyelocyticleukemia pages 1-2)

Suggested MAXO terms (examples; mapping suggestions)

  • All-trans retinoic acid therapy (differentiation therapy)
  • Arsenic trioxide therapy
  • Combination drug therapy (ATRA + ATO)
  • Supportive care for coagulopathy / transfusion support
  • Molecular monitoring (PCR-based MRD testing)

13. Prevention

No established primary prevention strategies were extractable from the retrieved evidence, consistent with APL being largely a sporadic, somatic-fusion malignancy. Secondary/tertiary “prevention” in practice centers on early suspicion, immediate ATRA initiation, aggressive management of coagulopathy, and molecular MRD monitoring to detect relapse early. (iyer2023thetreatmentof pages 1-2, kegyes2024mrdinacute pages 6-7)

14. Other species / natural disease

No naturally occurring APL analog in non-human species was identified in the retrieved evidence.

15. Model organisms and experimental systems

Cell line models

Reviews and mechanistic studies reference use of cell lines as core discovery tools to establish dominance of PML‑RARA and to probe response/resistance mechanisms to ATRA/ATO. (bercier2024historyofdeveloping pages 4-6, dai2023targetinghdac3to pages 1-2)

Mouse and xenograft models

  • A 2024 review notes that transgenic mouse models expressing PML‑RARA in the myeloid lineage can mimic APL and have been used to show that PML‑RARA can be a solitary initiating oncogenic event in appropriate contexts. (bercier2024historyofdeveloping pages 6-7)
  • A 2023 mechanistic paper used patient-derived xenograft (PDX) approaches (including serial transfers) to test how modulating HDAC3 affects PML‑RARα degradation and therapy resistance. (dai2023targetinghdac3to pages 1-2)

Model limitations (from available evidence)

The retrieved evidence does not provide structured limitations analyses; however, the consistent emphasis on early death/coagulopathy as a dominant real-world outcome determinant implies that animal/cell models may incompletely capture the health-system and supportive-care drivers of early mortality.

Expert opinions and authoritative synthesis (2023–2024 prioritized)

Recent authoritative reviews converge on two major points: 1) APL is highly curable in principle with ATRA+ATO-based molecularly targeted therapy (often quoted as >90% long-term survival in contemporary series), making it a flagship of targeted differentiation therapy. (iyer2023thetreatmentof pages 1-2, ghiaur2024acutepromyelocyticleukemia pages 1-2) 2) Early death remains the critical barrier to realizing these cure rates in real-world practice; high-quality supportive care and rapid initiation of ATRA are repeatedly highlighted as key interventions to close the trial–real-world gap. (iyer2023thetreatmentof pages 1-2, guarnera2024acutepromyelocyticleukemialike pages 1-2, gill2023acutepromyelocyticleukaemia pages 1-2)

Key recent statistics (quick list)

  • Annual APL incidence average 0.32 per 100,000 in a population study (1991–2021). (gill2023acutepromyelocyticleukaemia pages 1-2)
  • APL proportion of AML reported as ~8–15% (review). (guarnera2024acutepromyelocyticleukemialike pages 1-2)
  • Early deaths (first 30 days): 144 in a 1991–2021 population cohort; predominantly in ATRA-based induction era. (gill2023acutepromyelocyticleukaemia pages 1-2)
  • Overall survival in that cohort: 5-year 68.1%, 10-year 63.3%; post‑30‑day OS: 5-year 84.0%, 10-year 78.1%. (gill2023acutepromyelocyticleukaemia pages 1-2)
  • Chemotherapy-free ATRA‑ATO vs ATRA‑ATO+chemotherapy trial: 97% CR in both arms; 2‑year DFS/EFS ~98/95% vs 97/92% (all-risk), and high-risk DFS/EFS 94/85% vs 87/78%. (guarnera2024acutepromyelocyticleukemialike pages 1-2)

References (URLs and publication dates)

The principal sources used in this report are open-access review articles and population-based studies with embedded URLs in citations, including: * Iyer SG et al. Frontiers in Oncology (Jan 2023). https://doi.org/10.3389/fonc.2022.1062524 (iyer2023thetreatmentof pages 1-2, iyer2023thetreatmentof pages 2-4) * Gill H et al. BMC Cancer (Feb 2023). https://doi.org/10.1186/s12885-023-10612-z (gill2023acutepromyelocyticleukaemia pages 1-2) * Bercier P, de Thé H. Cancers (Mar 2024). https://doi.org/10.3390/cancers16071351 (bercier2024historyofdeveloping pages 4-6, bercier2024historyofdeveloping pages 6-7) * Ghiaur A et al. Cancers (Mar 2024). https://doi.org/10.3390/cancers16061160 (ghiaur2024acutepromyelocyticleukemia pages 1-2) * Kegyes D et al. Cancers (Sep 2024). https://doi.org/10.3390/cancers16183208 (kegyes2024mrdinacute pages 6-7) * Guarnera L et al. Cancers (Dec 2024). https://doi.org/10.3390/cancers16244192 (guarnera2024acutepromyelocyticleukemialike pages 1-2) * Dai B et al. Cell Death & Differentiation (Mar 2023). https://doi.org/10.1038/s41418-023-01139-8 (dai2023targetinghdac3to pages 1-2) * de Almeida TD et al. Future Pharmacology (Feb 2023). https://doi.org/10.3390/futurepharmacol3010012 (almeida2023acutepromyelocyticleukemia pages 1-2)

References

  1. (iyer2023thetreatmentof pages 1-2): Sunil Girish Iyer, Laila Elias, Michele Stanchina, and Justin Watts. The treatment of acute promyelocytic leukemia in 2023: paradigm, advances, and future directions. Frontiers in Oncology, Jan 2023. URL: https://doi.org/10.3389/fonc.2022.1062524, doi:10.3389/fonc.2022.1062524. This article has 70 citations.

  2. (guarnera2024acutepromyelocyticleukemialike pages 1-2): Luca Guarnera, Emiliano Fabiani, Giulia Falconi, Giorgia Silvestrini, Maria Luigia Catanoso, Mariadomenica Divona, and Maria Teresa Voso. Acute promyelocytic leukemia-like aml: genetic perspective and clinical implications. Cancers, 16:4192, Dec 2024. URL: https://doi.org/10.3390/cancers16244192, doi:10.3390/cancers16244192. This article has 2 citations.

  3. (gill2023acutepromyelocyticleukaemia pages 1-2): Harinder Gill, Radha Raghupathy, Carmen Y.Y. Lee, Yammy Yung, Hiu-Tung Chu, Michael Y. Ni, Xiao Xiao, Francis P. Flores, Rita Yim, Paul Lee, Lynn Chin, Vivian W.K. Li, Lester Au, Wing-Yan Au, Edmond S.K. Ma, Diwakar Mohan, Cyrus Rustam Kumana, and Yok-Lam Kwong. Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with atra and oral-ato from 1991 to 2021. BMC Cancer, Feb 2023. URL: https://doi.org/10.1186/s12885-023-10612-z, doi:10.1186/s12885-023-10612-z. This article has 38 citations and is from a peer-reviewed journal.

  4. (almeida2023acutepromyelocyticleukemia pages 1-2): Tâmara Dauare de Almeida, Fernanda Cristina Gontijo Evangelista, and Adriano de Paula Sabino. Acute promyelocytic leukemia (apl): a review of the classic and emerging target therapies towards molecular heterogeneity. Future Pharmacology, 3:162-179, Feb 2023. URL: https://doi.org/10.3390/futurepharmacol3010012, doi:10.3390/futurepharmacol3010012. This article has 10 citations.

  5. (bercier2024historyofdeveloping pages 4-6): Pierre Bercier and Hugues de Thé. History of developing acute promyelocytic leukemia treatment and role of promyelocytic leukemia bodies. Cancers, 16:1351, Mar 2024. URL: https://doi.org/10.3390/cancers16071351, doi:10.3390/cancers16071351. This article has 11 citations.

  6. (bercier2024historyofdeveloping pages 6-7): Pierre Bercier and Hugues de Thé. History of developing acute promyelocytic leukemia treatment and role of promyelocytic leukemia bodies. Cancers, 16:1351, Mar 2024. URL: https://doi.org/10.3390/cancers16071351, doi:10.3390/cancers16071351. This article has 11 citations.

  7. (ghiaur2024acutepromyelocyticleukemia pages 1-2): Alexandra Ghiaur, Cristina Doran, Mihnea-Alexandru Gaman, Bogdan Ionescu, Aurelia Tatic, Mihaela Cirstea, Maria Camelia Stancioaica, Roxana Hirjan, and Daniel Coriu. Acute promyelocytic leukemia: review of complications related to all-trans retinoic acid and arsenic trioxide therapy. Cancers, 16:1160, Mar 2024. URL: https://doi.org/10.3390/cancers16061160, doi:10.3390/cancers16061160. This article has 17 citations.

  8. (iyer2023thetreatmentof pages 2-4): Sunil Girish Iyer, Laila Elias, Michele Stanchina, and Justin Watts. The treatment of acute promyelocytic leukemia in 2023: paradigm, advances, and future directions. Frontiers in Oncology, Jan 2023. URL: https://doi.org/10.3389/fonc.2022.1062524, doi:10.3389/fonc.2022.1062524. This article has 70 citations.

  9. (dai2023targetinghdac3to pages 1-2): Bo Dai, Feng Wang, Ying Wang, Jiayan Zhu, Yunxuan Li, Tingting Zhang, Lu Zhao, Li-Ling Wang, Wen-hui Gao, Jun Yu Li, A. Liang, Hongming Zhu, Ke Li, and Jiong Hu. Targeting hdac3 to overcome the resistance to atra or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of pml-rarα. Cell Death & Differentiation, 30:1320-1333, Mar 2023. URL: https://doi.org/10.1038/s41418-023-01139-8, doi:10.1038/s41418-023-01139-8. This article has 33 citations and is from a domain leading peer-reviewed journal.

  10. (kegyes2024mrdinacute pages 6-7): David Kegyes, Praveena S. Thiagarajan, and Gabriel Ghiaur. Mrd in acute leukemias: lessons learned from acute promyelocytic leukemia. Cancers, Sep 2024. URL: https://doi.org/10.3390/cancers16183208, doi:10.3390/cancers16183208. This article has 3 citations.

OpenScientist ▸
1. Disease Information
openscientist-autonomous 52 citations 2026-05-04T23:51:31.744721

1. Disease Information

Overview

Acute Promyelocytic Leukemia (APL) is a distinct subtype of acute myeloid leukemia characterized by a block in myeloid differentiation at the promyelocyte stage, caused by the PML-RARA fusion oncoprotein resulting from the t(15;17)(q24;q21) chromosomal translocation. APL is classified as a unique entity in both the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues and the International Consensus Classification (ICC) of myeloid neoplasms. It is notable for its association with a severe hemorrhagic diathesis (DIC) and its remarkable sensitivity to targeted therapy with ATRA and ATO.

As described by Tomita et al., "Since the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) for the treatment of acute promyelocytic leukemia (APL), the overall survival rate has improved dramatically" (PMID: 23670176).

Key Identifiers

Database Identifier
OMIM #612376 (AML with t(15;17))
Orphanet ORPHA:520
ICD-10 C92.4 (Acute promyelocytic leukaemia [PML])
ICD-11 2A60.4 (Acute promyelocytic leukaemia with PML::RARA)
MeSH D015473 (Leukemia, Promyelocytic, Acute)
MONDO MONDO:0010521
NCI Thesaurus C3182

Synonyms and Alternative Names

  • Acute Promyelocytic Leukemia (APL)
  • AML-M3 (FAB classification)
  • AML with t(15;17)(q24;q21); PML-RARA
  • AML with PML::RARA fusion
  • Acute progranulocytic leukemia
  • APL with PML-RARA

Information Source

This report is derived from aggregated disease-level resources including peer-reviewed literature, clinical trial data, disease registries (SEER), and curated databases (OMIM, Orphanet, ClinVar, COSMIC).

2. Etiology

Disease Causal Factors

The primary cause of APL is the somatic acquisition of the balanced chromosomal translocation t(15;17)(q24;q21), which fuses the PML gene (on chromosome 15q24) with the RARA gene (on chromosome 17q21). This translocation creates the PML-RARA fusion oncoprotein that is both necessary and sufficient for disease initiation, though additional cooperating mutations are typically required for full leukemic transformation.

As stated by the landmark review: "Acute promyelocytic leukemia (APL) is driven by the promyelocytic leukemia (PML)/retinoic acid receptor alpha (RARA) fusion oncoprotein" (PMID: 38503502). Further, "APL, accounting for 10-15% of the newly diagnosed AML cases, results from a balanced translocation, t(15;17)(q22;q12-21), which leads to the fusion of the promyelocytic leukemia (PML) gene with the retinoic acid receptor alpha (RARA) gene. The PML-RARA fusion oncoprotein induces leukemia by blocking normal myeloid differentiation" (PMID: 34193815).

Risk Factors

Genetic Risk Factors

  • FLT3-ITD mutations: Present in approximately 20-40% of APL cases; associated with higher WBC counts and the microgranular variant. The prognostic significance is debated in the ATRA+ATO era (PMID: 36539954; PMID: 26920716).
  • Additional chromosomal abnormalities (ACA): Found in up to 48% of cases by SNP-array; dup(8q24) is the most frequent (~23%), followed by del(7q33-qter) (~6%). Most ACA are infrequent (<=3%) but recurrent (PMID: 24959826).
  • PML breakpoint cluster region (bcr): Three main breakpoints -- bcr1 (intron 6, ~55%), bcr2 (exon 6, ~5%), bcr3 (intron 3, ~40%). The short isoform (bcr3) has been associated with increased relapse risk in some studies (PMID: 26920716).

Environmental Risk Factors

  • Prior chemotherapy with topoisomerase II inhibitors: Therapy-related APL (t-APL) arises after exposure to topoisomerase II inhibitors (e.g., mitoxantrone, etoposide, doxorubicin). Analysis of genomic breakpoints confirmed that "breakpoints in 5 mitoxantrone patients fell within an 8-bp hotspot region" and these were "preferential sites of topoisomerase IIalpha-mediated DNA cleavage in the presence of mitoxantrone" (PMID: 18650449). t-APL after mitoxantrone shows altered PML intron 6 breakpoint distribution (92% vs 61% in de novo, P=0.035).
  • Prior radiation therapy: Radiation combined with chemotherapy is the most common antecedent in t-APL (PMID: 15899774).
  • Age: Median age at diagnosis is approximately 40-44 years; both pediatric and elderly cases occur.
  • Sex: Slight male predominance in some series (male:female ratio ~3:1 in one single-center study) (PMID: 41111704).
  • Obesity: Some epidemiological data suggest association with AML risk generally, though APL-specific data are limited.

Protective Factors

No well-established genetic or environmental protective factors specific to APL have been identified. The somatic nature of the translocation means germline protective variants are not applicable. Avoidance of topoisomerase II inhibitors reduces t-APL risk. A chemotherapy-free ATRA/ATO approach reduces therapy-related myeloid neoplasm risk: "the incidence of t-MN in ATRA/ATO + chemo group was significantly higher compared with ATRA/ATO only group (5.97% vs. 0.0%, respectively; p = 0.0289)" (PMID: 39254828).

Gene-Environment Interactions

The primary gene-environment interaction in APL is the topoisomerase II inhibitor-mediated generation of DNA double-strand breaks at specific genomic loci within PML and RARA, leading to the pathogenic translocation. This mechanism has been directly demonstrated: breakpoints in therapy-related cases are "preferential sites of topoisomerase IIalpha-mediated DNA cleavage" (PMID: 18650449).

3. Phenotypes

Clinical Symptoms and Signs

Phenotype HPO Term Type Frequency Severity Onset
Bleeding diathesis / hemorrhage HP:0001892 (Abnormal bleeding) Symptom 35-100% Severe Acute
Disseminated intravascular coagulation HP:0005765 (DIC) Laboratory/Clinical 17-100% Severe Acute
Fever HP:0001945 (Fever) Symptom 55% Moderate Acute
Pancytopenia HP:0001876 (Pancytopenia) Laboratory Very frequent Variable Acute
Fatigue / generalized weakness HP:0003388 (Easy fatigability) Symptom 7.5% Moderate Acute
Dyspnea HP:0002094 (Dyspnea) Symptom 15% Moderate-Severe Acute
Altered sensorium (CNS hemorrhage) HP:0001259 (Altered consciousness) Clinical sign 2.5% Severe-Fatal Acute
Thrombocytopenia HP:0001873 (Thrombocytopenia) Laboratory Very frequent Moderate-Severe Acute
Leukocytosis (especially microgranular variant) HP:0001974 (Leukocytosis) Laboratory 20-42.5% (high-risk) Variable Acute
Ecchymoses / petechiae HP:0000978 (Bruising susceptibility) Physical Frequent Variable Acute

Clinical presentation data from a single-center study showed: "The most common presenting feature was fever (55%), followed by bleeding (35%), dyspnoea (15%), generalised weakness (7.5%), and altered sensorium (2.5%)" (PMID: 41111704).

Coagulopathy (The Hallmark Complication)

DIC is the most characteristic and dangerous feature of APL. "DIC is common in patients with acute leukemia, with prevalence ranging from 17 to 100% in acute promyelocytic leukemia (APL)" (PMID: 33860520). The coagulopathy involves a complex interplay of: - Procoagulant activity (tissue factor expression on promyelocytes) - Hyperfibrinolysis (annexin II overexpression) - Proteolytic degradation of coagulation factors

Thrombotic Complications

Thrombosis is an underrecognized complication: "Eleven of 75 patients (14.7%) developed thrombosis... Pulmonary embolism accounted for 36% of all thrombotic episodes" with "27% all-cause mortality" in those with thrombosis (PMID: 42007745).

Treatment-Related Phenotypes

Differentiation Syndrome (DS): Occurs in 20-57% of patients during ATRA/ATO induction. Manifestations include unexplained fever, acute respiratory distress, pulmonary infiltrates, hypotension, weight gain >5 kg, peripheral edema, acute renal failure, and pleural/pericardial effusions. "Differentiation syndrome occurred more frequently in the high-risk group than in the low-risk group (p=0.001)" (PMID: 41111704). DS "is a life-threatening complication of the therapy with differentiating agents" (PMID: 31373469).

QTc Prolongation: ATO-associated cardiac toxicity, requiring ECG monitoring.

Quality of Life Impact

APL at presentation causes severe impairment due to hemorrhagic risk, transfusion dependence, and hospitalization. However, long-term survivors who achieve molecular remission generally return to normal quality of life, making APL unique among AML subtypes.

4. Genetic/Molecular Information

Causal Genes

Gene HGNC ID Chromosome Role
PML (Promyelocytic Leukemia) HGNC:9113 15q24.1 Tumor suppressor; organizer of PML nuclear bodies
RARA (Retinoic Acid Receptor Alpha) HGNC:9864 17q21.2 Nuclear receptor; master regulator of myeloid differentiation

Pathogenic Variants

Primary Translocation -- t(15;17)(q24;q21): - Variant type: Balanced reciprocal chromosomal translocation (structural) - Origin: Somatic (acquired in hematopoietic progenitor cells) - Frequency: Present in ~95% of APL cases (PMID: 32215187) - Functional consequence: Dominant-negative / gain-of-function fusion oncoprotein

PML-RARA Breakpoint Cluster Regions: - bcr1 (PML intron 6 / long isoform): ~50-55% of cases - bcr2 (PML exon 6 / variable isoform): ~2.5-5% of cases - bcr3 (PML intron 3 / short isoform): ~40-47.5% of cases

One study found "distribution of breakpoint cluster region 1 (bcr1), bcr2, and bcr3 transcripts being 20 (50%), 1 (2.5%), and 19 (47.5%), respectively" (PMID: 41111704).

Variant Translocations (~5% of APL cases): - t(11;17)(q23;q21) -- PLZF-RARA (resistant to ATRA) - t(5;17)(q35;q21) -- NPM1-RARA - t(11;17)(q13;q21) -- NuMA-RARA - TTMV::RARA -- novel viral-mediated fusion (PMID: 40679585) - Complex three-way translocations involving additional chromosomes (PMID: 19727242) - Cryptic/masked translocations requiring RT-PCR for detection (PMID: 39858554; PMID: 8819070)

Resistance Mutations: - PML-B2 domain mutations (A216V, S214L, A216T) confer ATO resistance by interfering with arsenic binding (PMID: 26537301; PMID: 30824184) - RARA ligand-binding domain (LBD) mutations confer ATRA resistance (PMID: 23670176)

Cooperating Mutations

  • FLT3-ITD: ~20-40% of APL cases; associated with higher WBC counts
  • FLT3-D835: Tyrosine kinase domain point mutation
  • WT1 mutations: Occasional
  • NRAS/KRAS mutations: Signaling pathway activation

Modifier Genes

  • CD34, CD56, CD2 expression: Surface markers associated with high-risk APL and increased relapse risk (PMID: 26920716)
  • IRF8: Identified as a potent tumor suppressor in murine APL (PMID: 30266821)
  • MTSS1: Expression negatively regulated by PML-RARA through DNMT3B-mediated methylation; "DNMT3B, a negative regulator of MTSS1, showed strong binding to the MTSS1 promoter in PML-RARA positive but not AML1-ETO positive cells" (PMID: 25996952)
  • GAB2: Overexpressed in APL; "the PML::RARA fusion protein may activate GAB2 by directly binding to its 5' flanking region" (PMID: 40773291)

Epigenetic Information

PML-RARA is a master epigenetic repressor that recruits multiple chromatin-modifying complexes:

  • NuRD complex: "PML-RARa binds and recruits NuRD to target genes, including to the tumor-suppressor gene RARbeta2. In turn, the NuRD complex facilitates Polycomb binding and histone methylation at lysine 27" (PMID: 18644863)
  • HDAC recruitment: Histone deacetylase complexes maintain transcriptional silencing
  • DNMT3A/DNMT3B: DNA methyltransferase recruitment leading to promoter hypermethylation
  • Polycomb Repressive Complex (PRC2): H3K27me3 deposition at target gene promoters
  • 14q32 miRNA cluster hypermethylation: "APL-associated hypermethylation at the upstream differentially methylated region" leading to miRNA overexpression (PMID: 24493669)

Chromosomal Abnormalities

  • Primary: t(15;17)(q24;q21) -- present in ~95% of cases
  • Additional chromosomal abnormalities (ACA): Most common are trisomy 8, dup(8q24), del(7q); found in ~25-48% depending on detection method (PMID: 24959826)

5. Environmental Information

Environmental Factors

  • Topoisomerase II inhibitors: The best-characterized environmental cause of APL. Drugs including mitoxantrone, etoposide, doxorubicin, and epirubicin can generate the t(15;17) translocation through topoisomerase II-mediated DNA cleavage. Median latency from exposure to t-APL development: ~40 months (range 17-166 months) (PMID: 15899774).
  • Radiation therapy: Combined with chemotherapy in 65% of t-APL cases (PMID: 15899774).
  • Benzene exposure: Associated with AML risk generally; limited APL-specific data.
  • Pesticide exposure: Epidemiological associations reported.

Lifestyle Factors

No strong lifestyle-specific risk factors (smoking, diet, alcohol, exercise) have been specifically linked to APL, though these factors affect AML risk broadly.

Infectious Agents

Recently, Torque Teno Mini Virus (TTMV), a member of the Anelloviridae family, has been identified as creating a novel TTMV::RARA fusion that drives an APL-like phenotype: "the precise pathogenic mechanisms of this ubiquitous symbiotic virus warrant further investigation" (PMID: 40679585). This represents a novel viral-mediated mechanism for generating oncogenic RARA fusions.

6. Mechanism / Pathophysiology

Molecular Pathways

The pathogenesis of APL involves a cascade from chromosomal translocation to leukemic transformation:

Upstream (Initiating Event):

t(15;17) translocation
    |
    v
PML-RARA fusion oncoprotein
    |
    +---> Transcriptional repression of RARa target genes
    |         (blocks differentiation)
    |
    +---> Disruption of PML nuclear bodies
    |         (impairs tumor suppression: p53, senescence, DNA repair)
    |
    +---> Epigenetic silencing
              (NuRD, HDAC, DNMT, Polycomb recruitment)

Downstream (Leukemic Phenotype):

Differentiation block at promyelocyte stage
    +---> Accumulation of malignant promyelocytes
    +---> Procoagulant activity (tissue factor, annexin II)
    +---> DIC / hemorrhagic coagulopathy
    +---> Bone marrow failure (cytopenias)

"Mechanistically, PML-RARa acts as a transcriptional repressor of RARa and non-RARa target genes and antagonizes the formation and function of PML nuclear bodies that regulate numerous signaling pathways" (PMID: 24344243).

Key Signaling Pathways Involved

Pathway Role in APL GO Term
Retinoic acid signaling Blocked by PML-RARA GO:0048384 (retinoic acid receptor signaling pathway)
PML nuclear body function Disrupted GO:0016605 (PML body)
Myeloid differentiation Arrested GO:0030099 (myeloid cell differentiation)
Apoptosis / senescence Impaired GO:0006915 (apoptosis); GO:0090398 (cellular senescence)
SUMOylation pathway Key therapeutic target GO:0016925 (protein sumoylation)
TGF-beta signaling Drives podoplanin expression, coagulopathy GO:0007179 (TGF-beta receptor signaling)

Cellular Processes

  • Differentiation block: PML-RARA suppresses PU.1, a critical transcription factor for myeloid differentiation. "PML-RARA suppressed PU.1 expression, while treatment of APL cell lines and primary cells with all-trans retinoic acid (ATRA) restored PU.1 expression and induced neutrophil differentiation" (PMID: 16352814).
  • Proliferation: "PML/RARa increases the cell proliferation and blocks the differentiation through activating MYB expression" (PMID: 30335887).
  • Self-renewal: APL cells acquire stem cell properties. Computational analysis revealed "APL cells show stem cell properties with respect to gene expression and transcriptional regulation" (PMID: 20508621).

Protein Dysfunction

PML-RARA Fusion Protein: - Acts as a dominant-negative repressor of wild-type RARA function - Blocks ligand-dependent transcriptional activation at physiological retinoic acid concentrations - Disrupts PML nuclear body assembly and tumor suppressor network - Recruits corepressor complexes (NCoR/SMRT/HDAC) at pharmacological ATRA concentrations, these are released

Mechanism of ATRA Action: At pharmacological doses (100-fold above physiological), ATRA binds PML-RARA and: (1) releases corepressor complexes, (2) triggers proteasomal and caspase-mediated degradation of PML-RARA, (3) restores PU.1 expression and granulocytic differentiation (PMID: 24433507; PMID: 16352814).

Mechanism of ATO Action: ATO directly binds to cysteine residues in the PML B-box 2 domain. "PML B-box-2 structure reveals an alpha helix driving B2 trimerization and positioning a cysteine trio to form an ideal arsenic-binding pocket" (PMID: 37655965). This triggers: (1) enhanced PML SUMOylation, (2) PML nuclear body reformation, (3) RNF4-mediated ubiquitination and proteasomal degradation of PML-RARA, and (4) restoration of PML tumor suppressor function (PMID: 32223133).

Epigenetic Changes

PML-RARA recruits a hierarchy of epigenetic repressor complexes:

  1. NuRD complex (MBD3, HDAC1/2, CHD4): Directly recruited by PML-RARA to target promoters including RARbeta2 (PMID: 18644863)
  2. Polycomb Repressive Complex 2: Recruited secondarily via NuRD, deposits H3K27me3 marks
  3. DNA methyltransferases (DNMT3A/B): Generate aberrant DNA methylation at target loci
  4. 14q32 domain: Loss of imprinting with hypermethylation leading to miRNA overexpression (PMID: 24493669)

Molecular Profiling

Transcriptomics: Gene expression profiling reveals downregulation of secondary/tertiary granule genes as the first step in the differentiation block, plus increased cell cycle gene expression (PMID: 26088929). Single-cell multiomics has revealed "a gene regulatory circuit driving leukemia cell differentiation" in APL (PMID: 39984714).

Immunophenotype (Flow Cytometry): Classic APL shows CD13+, CD33+(bright), CD117+, CD64+/-, HLA-DR-, CD34- pattern. Four distinct patterns exist: hypergranular (high SSC), microgranular (low SSC, CD2+, CD34+), mixed, and bipopulation (PMID: 22535601).

7. Anatomical Structures Affected

Organ Level

Level Structure UBERON Term Involvement
Primary Bone marrow UBERON:0002371 Malignant promyelocyte accumulation
Primary Blood UBERON:0000178 Circulating blasts, DIC
Secondary Spleen UBERON:0002106 Extramedullary infiltration
Secondary Liver UBERON:0002107 Hepatic infiltration
Secondary Lymph nodes UBERON:0000029 Occasional involvement
Complications Brain (CNS) UBERON:0000955 CNS hemorrhage (leading cause of early death)
Complications Lung UBERON:0002048 Pulmonary hemorrhage, DS-related infiltrates
Complications Heart UBERON:0000948 ATO-related QTc prolongation
Complications Kidney UBERON:0002113 Acute renal failure in DS

Tissue and Cell Level

Cell Type Cell Ontology Term Role
Promyelocyte (malignant) CL:0000836 Primary neoplastic cell
Hematopoietic stem cell CL:0000037 Cell of origin
Common myeloid progenitor CL:0000049 Differentiation pathway
Neutrophil (blocked) CL:0000775 Maturation arrested
Megakaryocyte CL:0000556 Thrombocytopenia from BM infiltration
Erythroid precursor CL:0000764 Anemia from BM infiltration

Subcellular Level

Compartment GO Term Role
PML nuclear bodies GO:0016605 Disrupted by PML-RARA; key therapeutic target
Nucleus GO:0005634 Transcriptional repression complex formation
Proteasome GO:0000502 Degradation of PML-RARA upon treatment

8. Temporal Development

Onset

  • Typical age of onset: Median ~40-44 years; occurs across all ages (pediatric to elderly)
  • Onset pattern: Acute -- APL is a hematological emergency with rapid onset of symptoms, particularly hemorrhagic coagulopathy
  • Pediatric APL: Accounts for ~5-10% of pediatric AML

Progression

  • Without treatment: Rapidly fatal (days to weeks), primarily from hemorrhagic complications
  • With ATRA/ATO treatment:
  • Induction phase (28-60 days): Achievement of hematologic then molecular complete remission
  • Consolidation (2-4 cycles): Deepening of molecular response
  • Maintenance (optional in ATRA/ATO era): ATRA with or without low-dose chemotherapy

Disease Course

  • Acute onset -> Induction therapy -> Complete remission (92-95%) -> Consolidation -> Molecular remission (>99%) -> Long-term cure (>90%)
  • Early death window: First 30 days -- the critical period; "Patients who survive the initial month generally achieve excellent long-term outcomes" (PMID: 41440532)
  • Relapse risk: Overall ~5-10%; higher in high-risk patients (WBC >10,000/uL)
  • Disease duration: Potentially curable (self-limited with treatment)

Remission Patterns

  • Treatment-induced remission: >90% with ATRA/ATO
  • Molecular remission: Achieved in ~99% after consolidation (PMID: 41564856)
  • Spontaneous remission: Not observed

9. Inheritance and Population

Epidemiology

Metric Value Source
Incidence ~0.7-1.0 per 100,000 per year (all AML); APL = 10-15% of AML SEER, Orphanet
Prevalence Rare disease (Orphanet) Orphanet
Median age at diagnosis ~40-44 years Multiple series
Pediatric proportion ~5-10% of pediatric AML Registry data

Genetic Inheritance

APL is a somatic, acquired disease -- the t(15;17) translocation arises somatically in hematopoietic progenitor cells. It is: - Not inherited (no germline transmission) - Not familial (no Mendelian inheritance pattern) - Penetrance/expressivity: Not applicable (somatic mutation) - Carrier frequency: Not applicable

Population Demographics

  • Ethnicity: Higher incidence reported in Hispanic/Latino populations compared to other ethnic groups in the United States
  • Geographic distribution: Worldwide; slightly higher proportions of AML cases being APL reported in Latin America, Spain, and Italy
  • Sex ratio: Approximately 1:1 to slight male predominance; one series showed 3:1 male:female (PMID: 41111704)
  • Age distribution: Bimodal peak in young adults and middle age; relatively young compared to other AML subtypes

10. Diagnostics

Clinical Tests

Laboratory Tests: - Complete blood count (CBC): Reveals pancytopenia or leukocytosis (microgranular variant); abnormal promyelocytes on peripheral smear - Coagulation studies: Prolonged PT, PTT; low fibrinogen; elevated D-dimer; DIC score assessment - Peripheral blood smear: Abnormal promyelocytes with heavy azurophilic granulation, Auer rods, and bundles of Auer rods ("faggot cells") - Bone marrow aspirate: Hypercellular with >20% abnormal promyelocytes

Biomarkers: - PML-RARA fusion transcript: Gold standard for diagnosis and MRD monitoring - Podoplanin (PDPN): Novel diagnostic biomarker; "sensitivity and specificity were 80.7% and 71.43% by RQ-PCR, and 92.86% and 100% by flow cytometry" (PMID: 41684157) - TGF-beta1 serum levels: Elevated in APL patients (PMID: 41684157)

Pathology / Histology: - Hypergranular APL (classical): Promyelocytes with abundant azurophilic granules, Auer rods, bilobed nuclei - Microgranular/hypogranular variant: Bilobed nuclei with sparse or absent visible granules; often associated with leukocytosis

Genetic Testing

Recommended Approach (in order of priority for rapid diagnosis):

  1. Morphology + Flow Cytometry (rapid, <24 hours): CD13+, CD33+(bright), CD117+, HLA-DR-, CD34- pattern; "The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARalpha gene rearrangements" (PMID: 10329918)
  2. FISH for t(15;17) (24-48 hours): Confirms translocation
  3. RT-PCR for PML-RARA (definitive, <48 hours): Identifies breakpoint type (bcr1/2/3); essential for MRD monitoring
  4. Karyotyping (7-14 days): Identifies additional cytogenetic abnormalities
  5. RNA sequencing / Whole-transcriptome sequencing: For cryptic rearrangements; essential when FISH and RT-PCR are negative but morphology is suggestive (PMID: 39858554; PMID: 41777660)

Critical diagnostic caveat: Cryptic/masked translocations exist where "karyotype and fluorescence in situ hybridization (FISH) using standard probes" are negative, but "RT-PCR revealed a cryptic PML-RARA" -- "This case highlights the importance of performing confirmatory testing in FISH-negative cases of suspected APL" (PMID: 39858554).

Clinical Criteria

Risk Stratification -- Modified Sanz Criteria:

Risk Group WBC (x10^9/L) Platelets (x10^9/L)
Low <=10 >40
Intermediate <=10 <=40
High >10 Any

Differential Diagnosis

Condition Distinguishing Feature
AML with maturation (AML-M2) HLA-DR+, CD34+; no PML-RARA
Acute monocytic leukemia (AML-M5) CD14+, HLA-DR+; monocytic morphology
AML with other RARA fusions (PLZF-RARA, NPM1-RARA) Different fusion partners; may be ATRA-resistant
HLH / TTP Different morphology; no Auer rods

11. Outcome / Prognosis

Survival and Mortality

The prognosis of APL has been revolutionized: "The discovery and clinical application of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) have dramatically improved the prognosis of APL, increasing the 5-year overall survival rate from less than 35% to over 90%" (PMID: 40623894).

Outcome Metric Pre-ATRA Era ATRA+Chemo Era ATRA+ATO Era
Complete remission rate ~75% ~90% ~95%
5-year OS <35% ~80% >90-95%
Relapse rate High 10-20% <5%
Early death rate (clinical trials) High 5-10% ~5%
Early death rate (real world) Very high 15-30% Up to 30%

Prospective trial data: "Complete remission was achieved in 95.1% of patients. With a median follow-up of 55 months, 3-year disease-free survival (DFS) and overall survival (OS) were 93.6% and 95.0%, respectively" (PMID: 41564856).

Early Death -- The Major Remaining Challenge

"Despite cure rates exceeding 90% and the rarity of relapse or refractoriness, early death (ED)-occurring within 30 days of diagnosis-remains unacceptably high, reaching up to 30% in population-based studies. ED is the major barrier to universal cure, with fatal hemorrhage as the predominant cause, followed by infection, differentiation syndrome, and thrombosis" (PMID: 41440532).

Early Death Predictors: - Higher WBC count (most validated) - Older age - Elevated creatinine - Low albumin - Severe thrombocytopenia - Coagulopathy severity

Prognostic Factors

Factor Impact Evidence
WBC >10 x10^9/L (high-risk) Higher early death, relapse Sanz criteria
FLT3-ITD Debated in ATO era PMID: 36539954
bcr3 (short) transcript Possibly higher relapse PMID: 26920716
CD56 expression Higher relapse risk PMID: 26920716
Molecular remission after consolidation Strong favorable predictor PMID: 39335185
DIC at diagnosis Impact on survival PMID: 36804019

Complications

  • Hemorrhagic events: CNS bleeding, pulmonary hemorrhage (leading cause of early death)
  • Differentiation syndrome: ~20-57% incidence; fatal in <5% with appropriate management
  • Thrombosis: 14.7% incidence; includes PE, DVT, catheter-related (PMID: 42007745)
  • Therapy-related myeloid neoplasms: 3.6% overall; only in patients receiving chemotherapy in addition to ATRA/ATO (PMID: 39254828)
  • ATO-related cardiac toxicity: QTc prolongation requiring monitoring
  • Hepatotoxicity: From ATRA and/or ATO

12. Treatment

Pharmacotherapy

Standard of Care -- ATRA + ATO (Chemotherapy-Free)

First-Line for Low/Intermediate-Risk APL (WBC <=10 x10^9/L): - Induction: ATRA (45 mg/m^2/day) + ATO (0.15 mg/kg/day IV) until complete remission - Consolidation: 4 cycles of ATRA + ATO - Maintenance: Generally not required with ATRA+ATO

Drug CHEBI Term Mechanism MAXO Term
All-trans retinoic acid (ATRA/Tretinoin) CHEBI:15367 Degrades PML-RARA; restores differentiation MAXO:0001298 (retinoid therapy)
Arsenic trioxide (ATO) CHEBI:30621 Binds PML B-box2; triggers SUMOylation and degradation of PML-RARA MAXO:0000058 (chemotherapy)
Dexamethasone CHEBI:41879 DS prophylaxis/treatment MAXO:0000644 (corticosteroid therapy)
Hydroxyurea CHEBI:44423 WBC control during induction MAXO:0000058 (chemotherapy)

First-Line for High-Risk APL (WBC >10 x10^9/L): - ATRA + ATO + anthracycline (idarubicin): Addition of chemotherapy for cytoreduction - Alternatively, ATRA + anthracycline-based chemotherapy (AIDA protocol)

"In most cases, APL is treated 'chemotherapy-free' with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). In high-risk patients, the combination of chemotherapy and ATRA is still standard" (PMID: 36030783).

The non-chemotherapy approach is validated: "The non-chemotherapy regimen of ATRA combined with ATO is a feasible method to cure APL patients" (PMID: 41234070).

Relapsed APL

In first relapse, ATO-based therapies demonstrated superior efficacy: "5-year OS was 73% in the ATO +/- ATRA group, 44% in the chemo-based group, and 29% in the ATRA +/- GO group" (PMID: 39335185). Gemtuzumab ozogamicin (anti-CD33 antibody-drug conjugate) is also used in relapse.

Advanced Therapeutics

Cell Therapy: - Allogeneic hematopoietic stem cell transplantation (allo-HSCT): Reserved for second or subsequent relapse; molecular remission before transplant improves outcomes (MAXO:0000016) - Autologous HSCT: Considered for molecular CR2 patients

Targeted Therapies: - FLT3 inhibitors (midostaurin, sorafenib): Under investigation for FLT3-mutated APL - Tamibarotene (Am80): Synthetic retinoid with higher binding affinity for PML-RARA than ATRA; tested for ATRA-resistant cases (PMID: 23670176)

Immunotherapy: - DNA vaccines targeting PML-RARA: Preclinical evidence shows "specific PML-RARA DNA vaccine combined with ATRA increases the number of long-term survivors with enhanced immune responses in a mouse model" (PMID: 26378812)

Supportive Care

  • Aggressive transfusion support: Platelets >30-50 x10^9/L; fibrinogen >1.5 g/L; cryoprecipitate/FFP for DIC
  • DS management: Dexamethasone 10 mg IV q12h at first sign; discontinue ATRA/ATO in severe cases (PMID: 31410848)
  • DS prophylaxis: Prednisone during induction (debated but increasingly recommended)
  • Cardiac monitoring: ECG for QTc prolongation with ATO

Treatment Strategy

Critical Principle -- Immediate ATRA Initiation: ATRA should be started immediately upon clinical/morphological suspicion of APL, before genetic confirmation. "ATRA treatment in the emergency department is associated with reduced early mortality in acute promyelocytic leukemia" (PMID: 41631884). Among 596 patients, "137 (23%) received early ATRA" within 24 hours, which was associated with improved 30-day mortality.

Treatment Outcomes

Metric ATRA+ATO (Low/Int Risk) ATRA+Chemo (High Risk)
CR rate ~95-98% ~90-95%
3-year DFS ~94-97% ~80-85%
3-year OS ~95-99% ~85-90%
Relapse rate ~2-5% ~10-15%
t-MN risk ~0% ~4-6%

13. Prevention

Primary Prevention

  • Avoidance of unnecessary topoisomerase II inhibitor exposure: Reduce risk of therapy-related APL
  • Chemotherapy-free ATRA/ATO regimens: Eliminate risk of therapy-related myeloid neoplasms from chemotherapy; "the incidence of t-MN in ATRA/ATO + chemo group was significantly higher compared with ATRA/ATO only group (5.97% vs. 0.0%, respectively; p = 0.0289)" (PMID: 39254828)

Secondary Prevention (Early Detection)

  • Rapid recognition of APL: Education of emergency physicians, hematologists, and pathologists to recognize the characteristic morphology and initiate empiric ATRA immediately
  • ATRA in the emergency department: Real-world data demonstrate reduced early mortality with early ATRA initiation (PMID: 41631884)
  • Coagulopathy awareness: Aggressive DIC management with blood product support before and during induction

Tertiary Prevention (Preventing Complications)

  • MRD monitoring: Regular RT-PCR monitoring for PML-RARA during and after treatment to detect molecular relapse early
  • DS prophylaxis: Corticosteroid prophylaxis during induction
  • Cardiac monitoring: ECG surveillance for ATO-induced QTc prolongation
  • Infection prophylaxis: Antimicrobial prophylaxis during neutropenic periods

Genetic Counseling

Not applicable for most cases as APL is a somatic, acquired disease. However, families of patients receiving topoisomerase II inhibitors for other cancers should be counseled regarding the small risk of t-APL.

Screening

No population-level screening is available or recommended for APL given its rarity and somatic nature. Monitoring for secondary malignancies in patients who received topoisomerase II inhibitors is prudent.

14. Other Species / Natural Disease

Naturally Occurring Disease

APL as defined by the PML-RARA fusion does not occur naturally in other species due to the species-specific nature of the chromosomal translocation. However, spontaneous myeloid leukemias with promyelocytic features have been rarely reported in veterinary oncology.

Comparative Biology

  • PML gene: Highly conserved across vertebrates; mouse Pml shares significant homology with human PML
  • RARA gene: Conserved across mammals; orthologous genes present in mouse (Rara), rat (Rara), zebrafish (raraa, rarab)
  • NCBI Gene IDs: Human PML (Gene ID: 5371); Human RARA (Gene ID: 5914); Mouse Pml (Gene ID: 18854); Mouse Rara (Gene ID: 19401)

15. Model Organisms

Mouse Models

Transgenic PML-RARA Mouse Models: Multiple murine models have been generated to study APL pathogenesis:

  1. hCG-PML/RARA transgenic mice: Express PML-RARA under the human cathepsin G promoter in myeloid cells. These mice develop APL-like disease with promyelocyte accumulation, DIC-like coagulopathy, and sensitivity to ATRA treatment. Used extensively for preclinical drug studies (PMID: 24201752; PMID: 26099922).

  2. MRP8-PML/RARA mice: Express fusion protein under the MRP8 promoter.

  3. Bone marrow transplant models: Retroviral transduction of PML-RARA into BM progenitors followed by transplantation into irradiated recipients (PMID: 28035072).

Model Characteristics

Phenotype Recapitulation: - Accumulation of abnormal promyelocytes in bone marrow and spleen - Sensitivity to ATRA-induced differentiation - ATO-induced PML-RARA degradation - Long latency (6-18 months), suggesting need for cooperating mutations - Transcriptome analysis of preleukemic promyelocytes revealed "PML/RARA had an overall limited impact on both the transcriptome and methylome" initially, with "down-regulation of secondary and tertiary granule genes as the first step engaging the myeloid maturation block" (PMID: 26088929)

Model Limitations: - Long latency to leukemia development (not fully penetrant) - Mouse promyelocytes differ from human in some phenotypic features - DIC and hemorrhagic complications not fully recapitulated - Species-specific differences in retinoic acid metabolism

Cell Line Models

Cell Line Origin Key Features
NB4 Human APL t(15;17)+; ATRA-sensitive; gold standard APL cell line
UB1 Human APL ATRA-sensitive
HL-60 Human AML ATRA-responsive but PML-RARA negative
U937-PR9 Human promonocytic + inducible PML-RARA Conditional PML-RARA expression model

Applications

Mouse and cell line models have been essential for: - Elucidating PML-RARA mechanism of leukemogenesis - Testing novel drug combinations (halofuginone, DNA vaccines) - Understanding ATRA and ATO mechanisms of action - Identifying cooperating mutations (FLT3-ITD, GAB2 amplification) - Studying resistance mechanisms - Preclinical validation of immunotherapy approaches

Key Findings -- Detailed Evidence

Finding 1: PML-RARA Fusion Oncoprotein Drives APL Through Dual Mechanisms

The t(15;17)(q24;q21) translocation, present in ~95% of APL cases, creates the PML-RARA fusion oncoprotein that drives leukemogenesis through two complementary mechanisms: (1) transcriptional repression of RARA target genes blocking myeloid differentiation at the promyelocyte stage, and (2) disruption of PML nuclear body formation and tumor suppressor function. "Mechanistically, PML-RARa acts as a transcriptional repressor of RARa and non-RARa target genes and antagonizes the formation and function of PML nuclear bodies that regulate numerous signaling pathways" (PMID: 24344243). The dual targeting of both moieties of the fusion protein by ATRA (targeting RARA) and ATO (targeting PML) underlies the exceptional efficacy of combination therapy.

Finding 2: ATRA+ATO Combination Has Transformed APL Into the Most Curable AML

The combination of ATRA and ATO has improved 5-year overall survival from <35% to >90-95%, representing one of the most dramatic therapeutic advances in cancer history. "Complete remission was achieved in 95.1% of patients. With a median follow-up of 55 months, 3-year disease-free survival (DFS) and overall survival (OS) were 93.6% and 95.0%, respectively" (PMID: 41564856). This chemotherapy-free approach also eliminates the risk of therapy-related secondary malignancies, with t-MN incidence of 0% compared to 5.97% in ATRA/ATO + chemotherapy groups (PMID: 39254828).

Finding 3: Early Death Remains the Principal Barrier to Universal Cure

Despite cure rates exceeding 90% in clinical trials, early death within 30 days of diagnosis remains unacceptably high, reaching up to 30% in population-based studies versus ~5% in clinical trials. Fatal hemorrhage is the predominant cause, followed by infection, differentiation syndrome, and thrombosis. "ED is the major barrier to universal cure, with fatal hemorrhage as the predominant cause" (PMID: 41440532). Higher WBC count and older age are the most consistently validated predictors. Immediate ATRA initiation in the emergency department is associated with reduced early mortality (PMID: 41631884).

Finding 4: PML-RARA Recruits Epigenetic Repressor Complexes

The fusion protein acts as an epigenetic master regulator by recruiting NuRD complex, DNA methyltransferases, and Polycomb complexes to silence differentiation genes. "PML-RARa binds and recruits NuRD to target genes, including to the tumor-suppressor gene RARbeta2. In turn, the NuRD complex facilitates Polycomb binding and histone methylation at lysine 27" (PMID: 18644863). Additionally, PML-RARA upregulates MYB through transcriptional and epigenetic mechanisms, driving proliferation (PMID: 30335887).

Finding 5: Therapy-Related APL Arises Through Topoisomerase II-Mediated DNA Cleavage

Therapy-related APL develops after exposure to topoisomerase II inhibitors with characteristic breakpoint patterns. Analysis confirmed that breakpoints in therapy-related cases were "preferential sites of topoisomerase IIalpha-mediated DNA cleavage in the presence of mitoxantrone" (PMID: 18650449). The altered PML intron 6 breakpoint distribution in t-APL (92% vs 61% in de novo, P=0.035) reflects drug-specific DNA damage patterns.

Evidence Base

Landmark and Key References

PMID Title/Topic Key Contribution
38503502 APL, Retinoic Acid, and Arsenic Comprehensive review of PML-RARA as driving oncoprotein
24344243 Synergy against PML-RARA Dual mechanism of transcriptional repression and PML-NB disruption
34193815 APL current treatment algorithms Treatment guidelines; 10-15% of AML
40623894 Cure for APL and China's contributions 5-year OS improvement from <35% to >90%
41564856 FBMTG-APL2017 Trial (Japan) 95.1% CR; 3-year DFS 93.6%, OS 95.0%
41440532 Predictors of Early Death ED up to 30% in real-world; hemorrhage predominant cause
33860520 DIC in Acute Leukemias DIC prevalence 17-100% in APL
18644863 NuRD/Polycomb in APL NuRD recruitment to target genes by PML-RARA
30335887 MYB regulation by PML-RARA Transcriptional and epigenetic MYB upregulation
18650449 t-APL breakpoint analysis Topoisomerase II-mediated mechanism of t-APL
37655965 Structural basis of ATO action PML B-box2 cysteine trio as arsenic-binding pocket
16352814 ATRA restores PU.1 PU.1 suppression and restoration mechanism
39254828 t-MN after APL treatment Chemotherapy-free approach eliminates t-MN risk
41631884 Early ATRA in emergency department Reduced early mortality with immediate ATRA
22535601 Flow cytometry patterns in APL Four distinct immunophenotypic patterns
15179005 APL: from fatal to curable Historical transformation of APL prognosis

Limitations and Knowledge Gaps

  1. Early death reduction: Despite decades of research, early hemorrhagic death remains stubbornly high in real-world settings (~20-30%), driven by delayed diagnosis, delayed ATRA initiation, and barriers to emergency department access. Effective strategies to bridge this gap between trial and real-world outcomes remain an urgent unmet need.

  2. High-risk APL optimization: Optimal treatment for high-risk APL (WBC >10,000/uL) in the ATRA+ATO era is not fully defined. Whether addition of chemotherapy or other cytoreductive agents can be replaced by ATO-based approaches remains under investigation.

  3. Resistance mechanisms: While PML-B2 mutations and RARA-LBD mutations are known, the full spectrum of resistance mechanisms is incompletely characterized, particularly for patients who relapse after ATRA+ATO.

  4. Variant RARA fusions: Non-PML::RARA fusions (e.g., PLZF-RARA, TTMV::RARA) are rare but pose diagnostic and therapeutic challenges, as some are ATRA-resistant. The optimal treatment approach for these variants is not standardized.

  5. Long-term ATO toxicity: Long-term effects of arsenic trioxide exposure on cardiovascular health, secondary malignancy risk, and other organ systems require continued follow-up of treated patients.

  6. Coagulopathy mechanisms: The precise molecular mechanisms linking PML-RARA to the unique hemorrhagic diathesis of APL are not fully elucidated, limiting ability to develop targeted interventions.

  7. APL in LMICs: Outcomes in low- and middle-income countries remain significantly worse due to infrastructure limitations, with 5-year OS as low as 17% in some African cohorts (PMID: 41413799).

Proposed Follow-up Experiments / Actions

  1. Emergency department ATRA protocols: Implement and study standardized empiric ATRA initiation protocols in emergency departments based on morphological suspicion, with outcomes assessment.

  2. Biomarker-guided DIC management: Develop real-time coagulopathy monitoring and treatment algorithms (dynamic DIC scoring) to reduce early hemorrhagic death.

  3. Chemotherapy-free high-risk APL trials: Evaluate whether ATRA+ATO with novel cytoreductive agents (e.g., venetoclax, gemtuzumab ozogamicin) can replace anthracyclines for high-risk APL.

  4. Single-cell multi-omics of coagulopathy: Apply single-cell transcriptomics and proteomics to dissect the molecular basis of APL-associated DIC, potentially identifying novel therapeutic targets.

  5. TTMV::RARA characterization: Systematically characterize the biology and optimal treatment of TTMV::RARA and other non-PML RARA fusions through international registry data collection.

  6. Global access initiatives: Develop and implement oral ATO formulations and simplified treatment protocols for low-resource settings to reduce the global APL mortality gap.

  7. Long-term survivorship studies: Establish prospective cohorts of APL survivors treated with ATRA+ATO to monitor for late cardiovascular, hepatic, and neurological effects of arsenic exposure.

  8. Resistance prevention: Investigate whether sequential or alternating ATRA/ATO dosing strategies could prevent emergence of PML-B2 resistance mutations in relapsed patients.

Report generated: 2026-05-05 Evidence base: 58+ peer-reviewed publications Primary literature sources: PubMed, OMIM, Orphanet, COSMIC, ClinVar